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How big is the problem of rectal cancer? 
 
The ultimate goal of surgical treatment for cancer is to be able to cure the disease while 
maintaining acceptable risks to the patient from the intervention required. Colorectal cancer is a 
frequent malignancy reported to cancer registries, being the second-most common in female 
patients and third-most common in male patients. In 2015 there were 15,604 new cases of 
colorectal cancer diagnoses in Australia and 3081 in New Zealand (1). About a third of these 
cases occur in the rectum. Invasion of an adjacent organ, defined as T4b disease, occurs in 10-
20% of cases (2). In order to achieve long-term survival it is critical that resection of the tumour 
with clear surgical margins be achieved. In the setting of T4b disease to achieve this will require 
a multi-visceral resection (MVR). Multi-visceral resection involves the en bloc resection of the 
tumour along with the invaded surrounding organ (3). It may range from a partial cystectomy or 
hysterectomy to a total pelvic exenteration (TPE) with resection of the rectum, anus, urogenital 
organs +/- boney and/or vascular resection. 
 
Early treatments 
Early management of rectal cancer involved attempts at resection via a perineal approach. As 
understanding of anatomy, anaesthesia and post-operative care improved surgery was to become 
more radical. The introduction of the abdomino-perineal resection by Miles in 1923 changed 
rectal cancer surgery by introducing the concept of a clear margin of resection. Sugarbaker 
published the first reported series of pelvic exenteration in 1946 (4). Here he presented 42 
patients where there “was either known involvement of the structure adjacent to the bowel or 
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such firm fixation to it that dissection between them was felt to entail too great a risk of entering 
disease”. He found that the patients treated with the multi-visceral resection were slightly 
younger (56y vs 61y), had much higher incidence of pre-operative weight loss and had a higher 
peri-operative mortality of 19% vs 9%. Given they had had a similar duration of symptoms to the 
standard-resection group he postulated that they had a more aggressive form of disease. 
 
Understanding of Total Mesorectal Excision and neoadjuvant therapies 
 
Heald’s popularisation of the concept of total mesorectal excision (TME) through the 1980s had 
a significant impact on the rate of local recurrence for rectal cancer (5). Prior to this local 
recurrence rates were as high as 27% as highlighted by the non-radiation arm of the Swedish 
rectal cancer trial (6). This awareness of TME-surgery through the 1980s and 1990s occurred in 
conjunction with trials looking at the use of radiotherapy for rectal cancer. Pre-operative 
radiation, be that short-course radiotherapy or long-course chemo-radiotherapy has shown to 
reduce rates of local recurrence and improve overall and disease-free survival (7-9). Although it 
comes with an increased risk of peri-operative complications and a worse functional outcome 
(10). For these reasons it is usually reserved for locally advanced rectal cancer, be that node-
positive disease or cases where the circumferential resection margin may be at risk. With a 
multidisciplinary approach to treatment, including improved preoperative imaging, judicious use 
of preoperative chemoradiation and standardisation of surgery, as well as adoption of total 
mesorectal excision (TME) the local recurrence rates in many tertiary centres has dropped below 






For rectal cancer patients the majority will have recurrences at or within 2 years of primary 
surgery (11). Heriot and colleagues reported that 43% of local recurrences were detected 
following 48 months from primary surgery, while Sagar and colleagues showed that 40% of LR 
occurred after 36 months (12). The risk profile for the primary tumours can predict the chance of 
recurrence. Patients with a threatened or involved circumferential resection margin (CRM), 
poorly differentiated adenocarcinoma, lympho-vascular invasion, venous invasion, perineural 
invasion, obstruction and perforation are at increased risk of local recurrence (13, 14). If 
preoperative Chemoradiation has been used prior to primary surgical resection then the 
recurrence may be delayed. While the majority of patients who undergo exenterative surgery are 
for rectal cancer, there are other indications for this surgery.  
These include:  
• Primary gynaecological cancers- advanced endometrial, ovarian, cervical and vaginal  
• Primary urological and sarcoma patients.  
• Lateral Lymph Nodes 
Lateral pelvic lymph nodes fall outside of the normal plane of dissection for rectal cancer. 
Modern imaging techniques, particularly MRI scans, are much better at identifying abnormal 
lateral pelvic lymph nodes on initial staging (15). The approach to abnormal lateral pelvic lymph 
nodes has not been standardised. Japanese studies suggest that the addition of lateral lymph-node 
dissection could reduce lateral recurrence. Other approaches have been to include the lateral 
pelvic sidewall in the radiation field. A multi-centre, retrospective cohort-study was performed 
by Ogura et al which looked at the role of lateral pelvic sidewall dissection for radiologically-
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abnormal lateral pelvic sidewall lymph nodes. This showed a lateral pelvic sidewall recurrence 
rate of 5.7% in those that had radiation, followed by TME + lateral pelvic sidewall resection, 
compared to 19.5% for those that did not undergo the lateral pelvic sidewall resection (16). Kim 
et al have subsequently performed a retrospective review of their management of pelvic-sidewall 
lymph nodes. This group routinely performed post-radiation MRI scans. Their results showed 
that, even in patients who had appeared to have responded on imaging, if resected, 16% of these 
patients still had viable tumour in their lateral pelvic nodes (17). In their patient-cohort the worst 
survival was in patients who had no response to neoadjuvant treatment, followed by those who 
had a good response and subsequently did not undergo sidewall dissection and finally the best 
results were in the group that had a good response and underwent a pelvic sidewall dissection. 
 
Direct invasion of tumour into the pelvic sidewall is difficult to manage. Due to the technical 
difficulties in achieving a clear margin when the tumour abuts or involves the major 
neurovascular structures of the pelvic sidewall many units would consider this un-resectable 
disease. In 1967 Barber and Brunschwig first reported 55 patients who underwent pelvic 
exenteration with en bloc common or external iliac vessel excision. Due to pelvic contamination 
and local factors only 5 of these 55 patients underwent graft reconstruction. 30-day mortality was 
high and only 5 patients remained alive at 5 years, all 5 of whom had only undergone venous 
excision (18). These initial poor results discouraged en bloc vascular resections for a generation 









Lateral Pelvic Sidewall Dissection in Pelvic Exenteration: 
 





















1967 New York, 
USA 
55 5 - - - - 35% 11 
Yamada et al 2001 Kagoshima, 
Japan 
17 0 - - - - 3 0 
Moore et al 2004 New York, 
USA 





36 8 6.6a 9 53 70 0 69 (19 
month 
F/U) 
Solomon et al 2015 Sydney, 
Australia 
200 23 3.5 10.25 67 82 0.5 35 
Tekkis et al 2017 London, UK 41  1.5 9 71 24 0 61 
aestimated from transfusion requirements   (adapted from a table by Brown et al (22)) 
 
 
Predicting locally invasive disease 
Not all surgeons are comfortable performing multi-visceral resections as it often requires 
operating outside of an area of familiarity. Mohan et al proposed three main reasons for this (20). 
It is not always possible to identify the need for MVR pre-operatively, intraoperatively it is 
difficult to identify true invasion from inflammatory adhesions, and MVR is associated with 
significant morbidity (20-22). Govindarajan et al found that the majority of patients with locally 
advanced rectal cancer in the USA did not receive a MVR, despite improved survival shown 
with MVR (23). In their analysis of the SEER database they found only 33% of patients with 
locally advanced colon and rectal cancers underwent MVR. They found an overall survival 
benefit for undergoing a MVR with no increase in short-term mortality compared to the group 
who did not undergo MVR (23). 
 
 10 
Intra-operative identification of true tumour invasion is difficult. Mohan et al performed a 
systematic review of 1575 patients across 22 studies where MVR was performed for colorectal 
cancer. 15 studies (1047 patients) differentiated between true tumour invasion and inflammatory 
adhesions with a true invasion rate of only 54.1% (20). Interestingly true invasion, versus 
inflammatory adherence was not seen to be an independent prognostic factor for survival in any 
of these studies on multivariate analysis. 
Complications 
The Clavien-Dindo classification system, modified in 2004 from the original complication 
classification proposal by Clavien in 1992 aims to create an objective and reproducible 
complication system for the post-operative course (24). Grade 1 and 2 complications are classed 
as “minor”, while grade 3 and 4 are classed as “major”. Deaths are classed as grade 5. Grade 1 
and 2 complications are able to be dealt with at the bedside +/- pharmacological intervention. 
Grade 3 (further subdivided into 3a and 3b) require invasive procedures, while grade 4a/b 
complications require ICU-level management. Previous publications regarding multi-visceral 
resections have reported overall complication rates ranging from 37-87% (20). Few have 
reported on the grade of complication and there is scarce data on the pattern or impact of 
complications on survival.  
The learning curve: Does volume matter? 
This area is slightly controversial. In general, it is believed that complex extended resections are 
best performed in specialised centres so that theatre staff are familiar with the nuances of the 
surgery and specialised equipment (25). Centralisation has been a theme in Europe with some 
healthcare systems centralising rectal cancers to maintain experience. The PelvEX collaborative 
recently reviewed 1,170 patients who had undergone a pelvic exenteration for locally recurrent 
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rectal cancer (LRRC) (3). Centres were split into low volume and high volume centres using a 
cut-off of 20 cases per-year. The results showed there was no significant difference between high 
volume and low volume centres in overall outcomes and that the R0 resection margin rates in 
both low and high volume centres (51% to 60%, 49-65%) improved over the 10 years of the 
study period (3). It should be noted, however, that these are specialised centres contributing to a 
multi-national dataset. 
Clear Margins and lymph nodes  
The ability to achieve clear resection (R0) margins is predictive of survival and should be the 
goal for colo-rectal cancer surgery. Harris et al reviewed 583 patients with recurrent rectal cancer 
and found overall survival were affected by the resection status with 5-yr OS rates of 44%, 26% 
and 10% for R0, R1, and R2 respectively (26). The PelvEX collaborative reported 3-yr OS rates 
of 48.1% (R0), 33.9% (R1) and 15% (R2) (10). Radwan et al reported on their experience with 
174 T4 primary rectal cancers and likewise showed improved 5-yr OS of 59.3% for R0, 
compared to 23% for R1 resection (27). Advanced-stage primary disease and pathologically 
positive lymph nodes are predictive factors for both local and distant relapse and reduced overall 
survival. 
Urology 
Urinary reconstruction may range from partial cystectomy with primary closure or ureteric re-
implantation through to cysto-prostatectomy with ileal-conduit urinary diversion with up to 53% 
of patients undergoing a pelvic exenteration requiring en bloc cystectomy (28). Nephro-
uretectomy may be required for direct invasion of the proximal ureter or kidney. These 
procedures are performed quite frequently for urological malignancies. Brown et al has reported 
higher rates of urological complications when performing urological resection and reconstruction 
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as part of a multivisceral resection when compared to reconstructions performed for primary 
urological cause (29). Most-typically involvement of the prostate has necessitated a cysto-
prostatectomy due to concerns about breakdown of a cysto-urethral anastomosis in the setting of 
previous irradiation. However, Turner and colleagues have shown that post-irradiation cysto-




Based on perceived gaps in the literature we sought to assess three specific questions relating to 
pelvic exenteration across 2 large quaternary high-volume centres.  
 
In Chapter One, an assessment is made of the changes in the nature of the surgery over three 
decades focusing on the surgical complexity, organs that are resected and the complication 
profile over that time frame. It will show that over time our outcomes for rectal cancer and non-
rectal cancer patients have improved and that the complexity of the surgery has increased. All of 
these factors are discussed in detail. 
Chapter Two examines ways to assess the overall outcomes and in particular the 1 and 5-year 
survival of patients who undergo this procedure. Univariate and multivariate analysis are 
performed to assess whether tumour type, patient factors or treatment factors influence disease 
free surgical and overall survival.  
Chapter Three, takes an in depth look into the complication profile of undertaking such major 
surgery.  In particular, complications are graded according to the Clavien-Dindo classification 
system for surgical complications. Other important KPI’s are focused on as well including 
anastomotic leaks, sepsis, intra-abdominal collections and death within 30 days. A logistic 
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regression analysis is performed to assess independent predictors of morbidity. This chapter will 
show that the major morbidity is acceptable and the mortality is negligible for patients 
undertaking exenterative surgery in high volume centres.  
Chapter Four, will specifically look at urological complications. Many of the exenterative 
procedures that are undertaken involve removing part of the urogenital system and hence a whole 
chapter is devoted to this subject. Again, this will look at predictors of poor outcomes, but also 
compare the non-urological with the urological intervention group.  
 
It is hoped that in addressing these questions around the evolution and complication profile of 
exenterative surgery that we as a specialist colorectal community can better inform our patients 
of the path we have taken, the trajectory we are on, as well as the measured and significant risks 
that this surgery poses. I also hope that the thesis will show that our outcomes are good and that 
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Objective: To examine the changes in exenterative surgery over three decades analysing 
oncological outcomes and whether changes in surgical approach have led to improved patient 
outcomes 
Background: Advances in surgical technology, perioperative care and pattern of disease 
recurrence have coincided with an evolutionary change in exenterative surgery.  
Methods: A review of prospectively maintained databases of pelvic exenteration surgery from 
1988 – 2018 at two high volume specialised institutions. The total cohort was divided into three 
major time points (1988- 2004, 2005-2010 and 2011 to 2018) to allow comparative analysis. 
Primary endpoints were overall survival in primary and recurrent disease at each time point. 
Secondary endpoints included anastomotic leak, blood transfusion, ileus, wound infection rates 
and evolution of case complexity. Data were analysed using R with a p<0.05 considered 
significant. 
Results: Six hundred and seventy patients underwent exenterative surgery. In 2011–2018 there 
was an increase in resection of recurrent malignancy with a continuous increase in gastro-
intestinal malignancies resected over each time period(p<0.001,<0.01) and a reduction in 
gynaecological malignancy(p<0.001). A significant increase in sacrectomy, pelvic sidewall 
resection and ileal conduit reconstruction was observed (p<0.01,<0.001). In 2005–2010  patients 
had increased rates of ileus and anastomotic leak(p<0.05). Patients undergoing resection for 
primary disease had improved overall survival at time points 1998-2004 and 2011–2018 
compared to those with recurrent disease(p=0.007,<0.001). Overall survival was significantly 
improved in patients with primary versus recurrent disease(p=0.022).  
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Conclusion: There has been a significant improvement in survival in patients undergoing pelvic 
exenteration surgery from primary disease. Case complexity has increased without significant 
morbidity. 
Key Words: Pelvic exenteration, rectal cancer, pelvic malignancy, recurrent rectal cancer, 























Achieving a complete resection with clear margins for pelvic malignancy has been well 
documented in the literature as the most important prognostic factor (1, 2). Pelvic exenteration is 
a procedure that allows en bloc multivisceral resection of contiguous locally advanced or 
recurrent pelvic malignancy. First described in the literature in 1948, it involves the resection of 
pelvic viscera in non disseminated pelvic lesions where radical margins are difficult to achieve 
due to tumour growth in close relation to or involving adjacent organs with reconstruction of 
gastrointestinal and genito-urinal tracts where necessary (3). To date, survival data suggests long 
term survival in greater than 50% of patients after exenterative surgery for rectal, gynaecological 
and urological malignancy (4). Due to the radical nature of the resection and reconstruction 
process there are inherently increased rates of morbidity and mortality when compared to 
standard isolated organ resection (5, 6). Mortality rates in excess of 20% have been outlined with 
perioperative morbidity ranging from approximately 30 – 80% (7-10).  
With the advent of neoadjuvant therapies, patient optimisation strategies, advances in 
surgical techniques, imaging and technology; pelvic exenteration surgery has been largely 
adapted since first inception.  Improved oncological and patient post-operative outcomes have 
been reported with such adaptations (11). The development and application of total mesorectal 
excision (TME) surgery and use of radiation for rectal cancer has coincided with a significant 
decline in the incidence of local pelvic recurrence over the last decade from 30% to rates as low 
as 5 – 10% (12-15). Furthermore, local failure and pattern of disease recurrence has also changed 
with diminishing central and TME component recurrences.  Similar patterns have been 
recognised in gynaecological malignancy with improved multidisciplinary treatment. All these 
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recent changes have led to the evolutionary customisation of exenteration surgery and 
reconstructive techniques for curative rather than palliative intent (16, 17).    
Such advances have taken place in a carefully coordinated approach with improved 
oncological and procedural outcomes reported to be possibly related to surgeon and hospital 
volume (18).  Moreover the development of specialist centres has produced good oncological 
and patient outcomes for extended radical resection for rectal cancers beyond the TME plane 
(19,20).  The PelvEX collaborative highlighting outcomes in such centres globally has recently 
reported a 3-year overall survival of 56.4% in patients with clear margins (21). Despite these 
improved figures exenteration surgery is not commonly practiced and slow to be adopted into 
many surgical units. This is possibly due to many studies such as PelvEX reporting short term 
oncological outcomes and also the lack of reported data highlighting changes in the evolution of 
exenteration surgery over a prolonged period of time. Furthermore with such marked adaptations 
in approach and technique there have been scant studies reporting associated oncological 
outcomes with such customisation of surgery over time. The authors propose that it is imperative 
that such changes in resection and reconstructive technique are not at the patient’s detriment.  
Therefore the aims of this study to examine the changes in exenterative surgery over three 
decades analysing oncological outcomes in different histological subtypes of pelvic malignancies 
in primary and recurrent disease. Changes in primary pathology excised with exenteration 
surgery, compartments resected, case complexity measured  by resection and reconstructive 
patterns and patient complications are reported throughout the study period to assess whether 







A review of prospectively maintained databases was undertaken to assess the outcome of 
patients who had undergone pelvic exenteration surgery.  The primary objectives were to analyse 
changes in resections performed in exenteration surgery and assess oncological and patient 
outcomes. Two tertiary referral centres with specialist experience in the surgical management of 
advanced rectal cancer and similar surgical approaches to exenterative surgery were included.  
These institutions were Christchurch Hospital (Christchurch, New Zealand) and Peter 
MacCallum Cancer Centre (Melbourne, Australia).  All patients were routinely discussed at a 
dedicated colorectal cancer multidisciplinary meeting.  The diagnosis of all cancers was based on 
preoperative radiological imaging and clinical assessment.  Data were prospectively collected at 
individual institutions.  Patient demographics (age, sex), neoadjuvant & adjuvant regimen, use of 
intraoperative radiotherapy (IORT), surgical intent, type of surgery including extended resections 
and the need for bony resection or flap reconstruction and complications were recorded.  
Histopathological assessment included margin status (R status), lymph node positivity, presence 
of lympho-vascular invasion (LVI) and degree of differentiation.  Centralised data were 
evaluated independently and analysed at the Peter MacCallum Cancer Centre, Melbourne, 
Australia. 
Definitions: 
The total cohort was divided into three major time points to allow for equal cohort numbers over 
each decade of surgery for comparative analysis. The cohorts were divided in those operated on 
from 1988- 2004, 2005-2010 and 2011 to 2018 respectively. Patients analysed included 
pathologies of Gastrointestinal (GI), gynaecological, squamous cell carcinoma (SCC) and Other 
(Melanoma, Prostate, Sarcoma, GIST, Chordoma) and had surgically resected organs recorded 
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prospectively. Type of exenteration performed was defined by the seven intrapelvic 
compartments demonstrating the organs that are included in each compartment. They were 
classified as Anterior above peritoneal reflection (PR), Anterior below PR, Central, Posterior, 
Lateral, Inferior and Peritoneal Reflection (22). Overall survival (OS) was defined as the time 
from the date of surgery to the date of death from any cause.  Resection of primary disease was 
defined as newly diagnosed malignant process requiring up front pelvic exenteration based on 
clinical and radiological assessment. Recurrent disease was defined as newly diagnosed disease 
of similar histological characteristics as previously resected tumour with a RO margin.  
Histopathological evaluation considered a R0 resection as a circumferential resection margin 
(CRM) of >1mm.  R1 resection was the presence of microscopic residual disease defined as a 
CRM of ≤1mm, whereas R2 resection was the presence of macroscopic residual disease. 
Complexity of exenteration was defined by type of organs resected or the requirement of organ 
reconstruction. Complications were compiled prospectively. A wound infection is defined by the 
US Centre for Disease Control and Prevention (CDC) as surgical site infection (SSI) (23). This is 
further defined as superficial incisional SSI (recorded as grade1) deep incisional SSI (grade 2) 
organ/space SSI (grade3). Ileus was defined as functional obstruction of the gastrointestinal 
tract and especially the small intestine that is marked by the absence of peristalsis, is usually 
accompanied by abdominal pain, bloating, and sometimes nausea and vomiting, and typically 
occurs following abdominal surgery. Anastomotic leakage was defined as a defect of 
the intestinal wall at the anastomotic site to a communication between the intra- and extraluminal 




The primary endpoints were overall survival primary and recurrent disease and by histological 
subtype at each time point. Secondary endpoints included complication rates of anastomotic leak, 
blood transfusion requirement, ileus and wound infection rates and evolution of case complexity.  
Statistical Analysis: 
Data were analysed using R (version 3.0.3; R Development Core Team 2009).  Baseline 
characteristics were summarised using descriptive statistics, with the mean and standard 
deviation (SD) used for categorical variables and the median and range for continuous variables. 
Comparison of outcomes between two groups was performed using paired t-test and one-way 
Anova was used to analyse the means of three or more factors within the study with a p-value of 
less than 0.05 (p<0.05) considered significant.  Univariate and multivariate analysis was 
performed to examine the impact of one or multiple factors on outcome. The Kaplan-Meier 
method was used to estimate the OS curves for each histological subtype and in primary and 
recurrent disease and associated 95% confidence intervals were reported.  Univariate analysis of 
possible prognostic variables on OS was assessed using the log-rank test (or exact log-rank test 
for small group numbers) with hazard ratios obtained from the Cox proportional hazards model 
used to estimate hazard ratio (HR) for death. 
  
Results 
Patients were divided into three time points dependent on timing of exenterative surgery, 1988 – 
2004 (n=193), 2005 – 2010 (n=250) and 2011 – 2018 (n= 265, Table 1, Figure 1). A significantly 
increased number of males underwent exenteration surgery in the latest time period. Age, ASA 
scores and co-morbidities remained similar throughout all time points. A significant increase in 
resections performed for recurrent disease was observed in 2011 -2018 (p<0.01). The number of 
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node positive tumours (N1 & N2) resected have significantly increased over time (p>0.05). 
There has been an increase in sacrectomy and prostatectomy over time with significant reduction 
in anal, ovarian and uterine resections. Furthermore, a significant increase in lateral, central and 
central with posterior compartments were resected with a similar decrease in central with inferior 
compartment resection (p<0.01). Margin (R) status was accurately collected for 361 patients 
within this thesis. In patients undergoing exenteration for primary disease R0 (clear margin) was 
achieved 81.6% of cases with R1 (microscopic margin) achieved in 17.6% and R2 (macroscopic) 
in 0.8% of cases. In recurrent cancer patients requiring exenteration – R0 margin was 70.1% 
followed by R1 margin of 24.8% and R2 of 4.9%. 
 
 
1988 - 2004 2005 - 2010 2011 -2018 
 
Total 
N 193 29% 212 32% 265 40% 670  
         
Gender         
Male 66 34% 67 32% 142 54% 275 41% 
Female 127 66% 145 68% 99 37% 371 55% 
Unknown     24 9% 24 4% 
         
Age         









Median (Range) 64.8 (26.4 - 111.0) 64.7 (22.1 - 89.2) 61.9 (19.0 - 87.0) 63.6 (19.0 - 111.0) 
         
ASA Grade         
1 11 5.60% 25 11.79% 16 6.03% 52 7.76% 
2 108 55.90% 104 49% 102 38.49% 314 46.86% 
3 57 29.50% 63 29.71% 58 21.88% 178 26.56 
4 5 2.59% 5 2.35% 6 2.26% 16 2.38% 
x 11 5.60% 15 7.07% 59 22.26% 85 12.68% 
Co-morbidity         
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MI 15 7.77% 11 5.18% 16 6.03% 42 6.26% 
Stroke 7 3.62% 8 3.77% 6 2.26% 21 3.13% 
PVD 2 1% 2 0.94 3 1.13% 7 1.04% 
Asthma 11 5.60% 14 6.60% 8 3.01% 33 4.92% 
COPD 16 8.20% 6 2.83% 3 1.13% 25 3.73% 
Renal failure 6 3.10% 7 3.30% 5 1.88% 18 2.68% 
Diabetes 22 11.39% 22 10.37% 21 7.92% 65 9.70% 
Psychiatric disorder 12 6.21% 12 5.66% 9 3.39% 33 4.92% 
Smoker 23 11.91% 31 14.62% 24 9.05% 78 11.64% 
         
Tumour         
Primary 142 74% 166 78% 115 43% 423 63% 
Recurrent 51 26% 46 22% 150 57% 247 37% 
         
T         
0 105 54% 109 51% 9 3% 223 33% 
1 2 1% 0 0% 4 2% 6 1% 
2 6 3% 7 3% 18 7% 31 5% 
3 20 10% 22 10% 84 32% 126 19% 
4 60 31% 73 34% 92 35% 225 34% 
X 0 0% 1 0% 58 22% 59 9% 
         
N         
0 158 82% 161 76% 122 46% 441 66% 
1 25 13% 30 14% 42 16% 97 14% 
2 10 5% 17 8% 36 14% 63 9% 
X 0 0% 4 2% 65 25% 69 10% 
         
M         
0 181 94% 196 92% 225 85% 602 90% 
1 12 6% 16 8% 39 15% 67 10% 
         
Organs Resected         
Colon 29 15% 51 24% 52 20% 132 20% 
Rectum 148 73% 140 66% 180 68% 468 70% 
Anus 75 39% 40 19% 31 12% 146 22% 
Small intestine 26 13% 43 20% 65 25% 134 20% 
Vagina 49 25% 37 17% 50 19% 136 20% 
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Uterus 59 31% 73 34% 53 20% 185 28% 
Ovaries FP tubes 66 34% 101 48% 41 15% 208 31% 
Prostate 29 15% 31 15% 65 25% 125 19% 
Bladder 54 28% 50 24% 78 29% 182 27% 
Sacrum 30 16% 24 11% 60 23% 114 17% 
         
Compartments 
Resected 
        
Central 6 3% 7 3% 38 14% 51 8% 
central with posterior 29 15% 20 9% 70 26% 119 18% 
anterior above PR with 
anterior below PR  
25 13% 46 22% 24 9% 95 14% 
central with anterior 
below PR 
66 34% 89 42% 62 23% 217 32% 
anterior below PR 5 3% 8 4% 21 8% 34 5% 
anterior above PR with 
anterior below PR  
4 2% 7 3% 10 4% 21 3% 
lateral 3 2% 4 2% 34 13% 41 6% 




Table 1: Patient demographics, co-morbidities, tumour characteristics and organ/compartments 
resected. 
 
From 1998 to 2004 a significant proportion of patients (n=142) underwent exenterative 
surgery for primary disease compared to those with recurrent disease (n=51). A significant 
similar pattern was observed from 2005 – 2010 (n=183, n=67 respectively (p<0.01). There was a 
change in 2011 – 2018 with a significantly higher proportion of patients undergoing exenterative 




Figure 1: Total patient cohort at each time point and resection of primary or recurrent disease: There 
was a significantly higher proportion of primary diagnosed malignancy undergoing pelvic exenteration in 
1998 – 2004 and 2005 – 2010 (p<0.01). In 2011 – 2018 there has been a significant shift in resection of 
recurrent malignancy compared to primary disease (P<0.001).    
 
Throughout the study period there was a significant increase in exenteration surgery performed 
for GI related malignancies over each time point (1988 – 2004 n= 135, 2005 – 2010 n=161, 2011 
– 2018 n=225, p<0.01, Figure 2). There was no statistical increase in patients undergoing 
exenterative surgery for SCC and other malignancies at each time point (p=0.6872, p=0.6319 
respectively). There was a significant decrease in exenterative surgery being performed for 





Figure 2: Primary pathology resected: there has been a continuous increase in GI malignancies resected 
over each time period (p<0.01). There has been a similar amount SCC and Other malignancies 
(Melanoma, Prostate, Sarcoma, GIST, Chordoma) resected at each time point during the study period 
(p=0.687, p=0.61 respectively). Gynaecological related malignancies have significantly reduced from 
2005 – 2010 time point to 2011 – 2018 (p<0.001).  
 
 
Case complexity has increased over the study period. There has been a significant increase in 
patients undergoing sacrectomy in 2011 – 2018 (n=60, p<0.01, Figure 3). Urinary diversion and 
reconstruction with ileal conduit has also significantly increased in the latest time period (n=81, 
p<0.001). Similarly a significantly increased proportion of patients in 2011 – 2018 had pelvic 
sidewall resection performed (n=34, p<0.001). The number of patients undergoing flap 




Figure 3: Case complexity outlined by boney and sidewall resection and reconstruction. Throughout the 
study period there has been a significant increase in sacrectomy and pelvic sidewall resection (p<0.01 
and <0.001 respectively).  Patients undergoing flap reconstruction has remained similar throughout the 
study period (p=0.142). Ileal conduit reconstruction has significantly increased in the most recent time 
point 2011 – 2018 (p<0.01). 
 
Complications were recorded prospectively within the database during the study period. There 
was a significant increase in patients with postoperative ileus during 2005 – 2010 time point 
compared to other time points (p<0.001, Table 2). 25% of patients (n=52) experienced post-
operative ileus compared to 18% in 1988- 2004 and 17% in 2011 to 2018. Of the total cohort, 
20% of patients developed post-operative ileus. A significantly higher proportion of patients 
experienced an anastomotic leak during the same time period (n=10, p=0.006). Of patients that 
had a gastro-intestinal anastomosis performed (n=127) the anastomotic leak rate was 5%. The 
overall wound infection rate for the cohort was 19%. Wound infection rates were significantly 
higher in 2011 – 2018 (n=50, p<0.001). Superficial wound infections were significantly higher 
during this time period with less deep organ spaced infection (14% & 1% respectively). Deep 
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organ space infections were highest in 1988 – 2004 and 2005 – 2010. Blood transfusion 
requirement was significantly lower in 2005 – 2010 compared to other time points (p<0.01,  
Table 2). Mean transfusion was 0.943 of a unit (range 0-27units). 
 
Table 2: Complications encountered during each time point and total cohort:  Patients 
undergoing pelvic exenteration surgery during 2005 – 2010 had significantly increased rates of 
ileus compared to other time points (p<0.001). There were also increased rates of anastomotic 
leak at this during this time point. Incidence of total wound infections were significantly lower in 
2005 – 2010 time point (p<0.001). Blood transfusion requirement was significantly higher during 
1984 – 2004 and 2011 – 2018 time points (p<0.01). 
 
Overall survival for patients with primary and recurrent disease undergoing exenterative surgery 
was recorded during each time period and also for the total cohort. Patients with primary disease 
undergoing resection had a significantly improved survival in 1998 – 2004 and 2011 – 2018 than 
those undergoing operative intervention for recurrent disease (p=0.007, p<0.001, Figure 4).  
Complications 1998 - 2004 2005-2010 2011-2018  Total cohort P Value 
Ileus         0.001 
No 159 82% 160 75% 197 74% 516 77%  
Yes 34 18% 52 25% 44 17% 130 20%  
          
Anastomotic Leak         P=0.006 
No 190 98% 202 95% 250 94% 632 94%  
Yes 3 2% 10 5% 15 6% 14 6%  
          
Wound Infection         P<0.001 
No 150 78% 173 82% 191 72% 514 77%  
Grade 1 11 6% 14 6% 37 14% 62 9%  
Grade 2 25 13% 19 9% 10 4% 54 8%  
Grade 3 7 4% 6 3% 3 1% 16 2%  















Figure 4: Overall survival in primary (Red) and recurrent disease (Green): Patients undergoing 
resection for Primary disease had significantly improved overall survival at time points 1988-2004 and 
2011 – 2018 compared to those with recurrent disease (p=0.007, p<0.001 respectively). Overall survival 
for the total cohort was significantly improved in patients undergoing resection for primary disease 
versus recurrent disease (p=0.022).  
 
There was no significant difference in survival observed in those with primary versus recurrent 
disease during 2005 – 2010 (p=0.484). Within the total cohort those with primary resected 
disease had significantly improved survival than those with recurrent disease (p=0.022).  
Survival probability for each major histological subtype undergoing exenteration at each time 
point was measured. Those patients with gastrointestinal malignancy undergoing exenteration in 
2011 – 2018 had significantly improved survival compared to those undergoing surgery in 1988-
2004 and 2005 – 2010 (p<0.01, Figure 5). A similar pattern was observed in patients with 
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gynaecological malignancy having a significantly improved survival when undergoing resection 
in 2011-2018 compared to those in 1988 – 2004 and 2005 – 2011 (p<0.05). Patients with SCC 
and other malignancy (Melanoma, Prostate, Sarcoma, GIST, Chordoma) did not display any 
difference in survival when operated in each time point (p=0.793, p=0.667).   
  
 
Figure 5: Overall survival in each histological subtype at each time point. Patients undergoing pelvic 
exenteration with GI and Gynae diagnosed malignancy  had significant overall improved survival in 2011 
to 2018 compared to other time points (p<0.01 and p<0.05 respectively). SCC and other malignancy 







This large international combined series from established centres, specialising in pelvic 
exenterative surgery, presents good outcomes and describes the evolution of this technique for 
locally advanced pelvic tumours. Surgical intervention to treat locally advanced pelvic tumours 
has steadily been gaining momentum.  During the course of the last three decades, this study 
demonstrates advances in the operative strategies implemented and the types of pathology 
encountered.  There was a tendency towards performing exenterative surgery for recurrent 
disease during the latter years of this study (2011 to 2018) compared with the preceding time 
points.  The increasing complexity of the pathology encountered is also reflected by the 
expanding number of surgical components performed.  This correlation is demonstrated by the 
increasing number of sacrectomy, ileal conduits and lateral pelvic sidewall dissections 
performed.   
These increasing trends might mirror overcoming the surgical learning curve and therefore the 
technical challenges of the operative interventions evolve with increasing familiarity of the 
procedures. As surgeons become more comfortable with the techniques of exenterative surgery, 
the boundaries have been pushed, performing more radical surgery including cystectomy, 
sacrectomy and now lateral pelvic side wall resections.  The complexity management of the 
disease has also increased (recurrent versus primary) and an increasing willingness to perform 
exenterative surgery on higher risk patients (less ASA 1 & 2 patients). 
The surgery has also become more bespoke, with the aim to improve patient’s quality of life. 
During this study period, there has been an increasing trend towards sphincter preserving 
surgery, reflected by the downward trend in resecting the anus (39% to 12%) as exenterative 
surgery has evolved.  This might explain the slight increase in anastomotic leak rate between 
2005 to 2010 (5%) compared with 1988 to 2004, which corresponds with the initial downward 
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trend in resecting the anus.  As this technique has evolved and further reduction in resecting the 
anus, the anastomotic leak rate has decreased to the baseline.  Other efforts to improve patient’s 
quality of life are reflected in the development of techniques to resect the prostate enbloc and 
leave the bladder in situ and functioning (25). This strategy has been enabled by the development 
in the techniques for radical prostate surgery in prostate cancer. 
The increasing familiarity and expertise in exenterative surgery might also be reflected in the 
decrease utilisation of blood transfusion in the middle period of this study.  However, the 
adoption of expanding operative complexity, particularly with increasing pelvic side wall 
dissection and sacrectomy between 2010 to 2018, may also explain the increase in blood 
transfusion requirements during this time period, similar to the initial period (1988 to 2004). 
This current study also reports a significant overall survival in patients undergoing 
exenteration surgery for primary compared to recurrent disease. This improved survival was 
observed in patients undergoing resection in 1998 – 2004 and 2011 – 2018 and further borne out 
in the total cohort despite no difference in survival observed in patients operated within 2005 – 
2010. This observation could be reflected on the fact that there has been improved patient 
selection over the last decade despite the significant increase in patients with recurrent disease 
undergoing surgery within the two units. Throughout all time points there has been increased 
numbers of patients with GI pathology being resected however within the 2005- 2010 period 
there was a significant increase in operative intervention in patients with gynaecological related 
malignancy followed by a significant decline in the last decade. The authors postulate that this 
significant increase could potentially lead to worse survival in patients undergoing resection 
within the primary malignancy group during this time point. The literature to date has 
documented inferior survival in patients with gynaecological malignancy undergoing 
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exenterative surgery than primary organ resection or resection of other pathologies. A study by 
Westin et al reported five-year overall survival after pelvic exenteration was 40% in patients with 
gynaecological malignancy (26). The authors report that survival outcomes have not significantly 
improved despite improvements in technique and patient selection undergoing exenteration. 
Moreover, they state that non-modifiable factors associated with gynaecological malignancy at 
the time of exenteration are associated with poor survival. These outcomes have been mirrored in 
other studies (27, 28) A recent study reported an overall survival of 40.7% and cumulative 5-year 
overall survival of 38% in patients under exenterative surgery for primary and recurrent cervical 
carcinoma. In contrast patients undergoing exenterative surgery for GI related malignancies have 
superior overall oncological and survival outcomes.      
 This analysis documents a sustained increase in survival at each time point in patients 
undergoing intervention for primary and recurrent disease with an overall 5-year survival of 
greater than 75% or primary resected malignancy in the latest time point. These findings are 
reflected in other smaller studies analysing survival outcomes in primary and recurrent disease. 
Ferenschild et al report overall 5-year survival for primary locally advanced rectal cancer, 
recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45% respectively (29). 
Furthermore a more recent study comparing outcomes in rectal cancer patients under 
exenteration surgery highlight a significant reduced disease free survival in patients with 
recurrent rectal cancer compared to those with primary locally advanced disease (30). Recurrent 
rectal cancer patients continued to have significant worse DFS even after patients with R1 
resections were excluded. A study examining outcomes of 40 consecutive exenterations over a 
nine year period for locally advanced versus locally recurrent colorectal malignancy reported that 
5-year overall survival was significantly inferior in recurrent disease as apposed to upfront 
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advanced disease (58.7% vs. 11.8%, P = 0.022) (31). Similar to contemporary work from the 
PelvEX collaborative group and other centres, the authors report worse outcomes in recurrent 
disease and the importance of achieving an RO resection (1, 30, 32, 33).  
The five-year survival probability of each primary pathology was analysed at each time 
point to assess survival outcomes. The analysis demonstrates that patients operated on during this 
current time point (2011 – 2018) had significantly improved five-year survival in GI malignancy 
compared to other time points.  There was no change in survival in those operated in 1988 – 
2004 and 2005 – 2010. Moreover, patients with SCC and Other malignancy had similar five year 
survivals regardless of time point of operation.  Interestingly however the current study 
documents improved survival in patients undergoing exenteration for gynaecological malignancy 
during 2011 – 2018. With a significant reduction in the number of patients in the time point the 
authors postulate that improved patient selection for curative intent is likely to be the underlying 
reason for such a significant improved survival.  
There are limitations to this study, which need to be considered.  Firstly, interpretations of these 
results are limited somewhat by the degree of heterogeneity, both within each and between 
centres.  This includes the degree of heterogeneity of the patient populations, pathology, 
variations in the treatment strategies and surgical technique.  It is also important to acknowledge 
that the data is collected over a long time period (1988-2018), which may also introduce a degree 
of inherent bias, given the evolving treatment strategies over time, which have been described.  
However, there is a previous collaborative history (35, 36), with also a high degree of 





Pelvic exenterative surgery has undergone dramatic changes over the last three decades with its 
indications now expanding to include significantly increased cases of recurrent disease. Despite 
increased case complexity over time there has been no significant change in the associated 
complication profile. Patients undergoing upfront exenteration for primary disease continue to 
have improved survival compared to those undergoing resection of recurrent malignancy. 
Finally, patients with GI and gynaecological primaries have seen significant improved survival 
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Short running head:  Complications after pelvic exenteration 
 
Mini-Abstract: Our series adds to the increasing evidence that good outcomes can be achieved 
for pelvic exenterative surgery in locally advanced and recurrent pelvic malignancies.  A 
coordinated approach in specialist centres for beyond TME surgery demonstrates this is a safe 






BACKGROUND:  The oncological role of pelvic exenteration for locally advanced and 
recurrent pelvic malignancies arising from the anorectum, gynaecological or urological systems 
is now well established.  Despite this, the surgical community has been slow to accept pelvic 
exenteration, undoubtedly owing to concerns about high morbidity and mortality rates based on 
historical data.  Therefore, the aims of this study were to assess the general major complications 
and predictors of morbidity following exenterative surgery for locally advanced and recurrent 
pelvic malignancies. 
METHODS:  Data were collected from prospective databases at two high-volume institutions 
specialising in beyond TME surgery for locally advanced and recurrent pelvic malignancies 
between 1990 and 2015.  The primary outcome measures were major complications (Clavien-
Dindo 3 or above) and predictors for morbidity. 
RESULTS:  A total of 646 consecutive patients requiring exenterative surgery for local 
advanced pelvic malignancies were identified.  The median age was 63 years (range 19-89 
years), and the majority were female patients (371; 57.4%).  Five hundred and forty patients did 
not suffer a major complication (83.6%) following pelvic exenterative surgery.  One or more 
major complications were observed in the remaining 106 patients (16.4%).  The most common 
major complications were intra-abdominal collection (43.7%; n=59/135) and wound infection 
(14.1%; n=19/135).  The overall inpatient mortality rate was 0.46% (n=3/646).  Independent 
predictors for major morbidity following exenterative surgery for locally advanced or recurrent 
pelvic malignancies were squamous cell carcinoma of anus, sacrectomy, past history of 
peripheral vascular disease and requirement for blood transfusion.  
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CONCLUSION:  Our series adds to the increasing evidence that good outcomes can be 
achieved for pelvic exenterative surgery in locally advanced and recurrent pelvic malignancies.  
A coordinated approach in specialist centres for beyond TME surgery demonstrates this is a safe 
and feasible procedure, offering low major complication rates. 
 





















The oncological role of pelvic exenteration for locally advanced and recurrent pelvic 
malignancies arising from the anorectum, gynaecological or urological systems is now well 
established(1-3).  The beyond TME collaborative provides consensus on the definitions and 
principles of management of these complex patients, advocating an extended surgical resection 
beyond the TME plane to achieve a pathological R0 resection(1).  Extensive multi-visceral 
resection is often required to achieve clear resection margins (R0), which is the key predictor of 
long-term survival for locally advanced pelvic tumours(4, 5).  It is the only curative option for 
patients with locally advanced or recurrent pelvic malignancy. 
Since pelvic exenteration was first described in 1948, advances in healthcare have brought 
dramatic oncological improvements and reduced morbidity from what was previously deemed a 
palliative procedure(6, 7).  In recent decades, an attempt to offer a chance of cure to greater 
numbers of patients with more advanced disease has enabled the development of techniques for 
increasingly radical lateral neurovascular and bony pelvic excisions(8).  Current data 
demonstrate that long-term survival after pelvic exenteration is achievable in more than 50 per 
cent of selected patients with an acceptable quality of life(8, 9). 
Although pelvic exenteration clearly represents the treatment of choice in the modern era of 
medicine, accessibility to surgery for those with potentially curative local recurrence remains a 
concern(10).  Also, despite the encouraging figures, which are comparable to outcomes of 
hepatic metastasectomy, the surgical community has been slow to accept pelvic exenteration, 
undoubtedly owing to concerns about high morbidity and mortality rates based on historical 
data(7, 8).  Therefore, the aims of this study were to assess the general major complications and 
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A retrospective review of prospectively maintained databases was undertaken to assess the 
outcome of patients who have undergone pelvic exenterative surgery for locally advanced or 
recurrent pelvic malignancies.  The primary objectives were to identify the general major 
complications and predictive factors for morbidity following pelvic exenterations.  Two tertiary 
referral centres with specialist experience in the surgical management of advanced pelvic 
tumours, similar surgical approaches to beyond TME surgery and previous collaborative 
experience(2, 11) were included.  These institutions were Christchurch Hospital (Christchurch, 
New Zealand) and Peter MacCallum Cancer Centre (Melbourne, Australia).  All patients were 
routinely discussed at a dedicated pelvic exenterative surgery multidisciplinary meeting.  The 
diagnosis of locally advanced pelvic tumour was based on preoperative radiological imaging and 
clinical assessment.  Data were prospectively collected at individual institutions.  Patient 
demographics (age, sex, ASA), comorbidities, primary or recurrent tumour, tumour type, 
neoadjuvant & adjuvant regimen, organs resected and type of surgery including the need for 
urological or bony resection or flap reconstruction were recorded.  Furthermore, the type of 
general complications (number of major complications: wound infection, pneumonia, urinary 
tract infection, sepsis, myocardial infarction, arrhythmias, pulmonary embolus, stroke, acute 
kidney injury, acute respiratory distress syndrome, anastomotic leak, intra-abdominal collection, 
post-operative bleeding and small bowel obstruction) were recorded.       
Definitions: 
Operations were considered exenterative when the primary organ and at least one of the 
surrounding organs was removed en-bloc (rectum, bladder, prostate, uterus, vagina, sacrum, 
small bowel, ureter, iliac vessels, ovary and fallopian tube removal)(11). 
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Patients analysed included the following pathologies; gastrointestinal adenocarcinoma, anal 
squamous cell carcinoma (SCC), gynaecological (ovarian, cervical, uterine or vaginal) and other 
malignancy (melanoma, prostate, sarcoma, GIST and chordoma) and had surgically resected 
organs recorded prospectively. 
Resection of primary disease was defined as newly diagnosed malignant process requiring up 
front pelvic exenteration based on clinical and radiological assessment.  Recurrent disease was 
defined as newly diagnosed disease of similar histological characteristics as previously resected 
tumour with an R0 margin. 
Complications occurring within 30-days postoperatively or during the inpatient care for the index 
operation were graded according to the Clavien-Dindo classification system for surgical 
complications(12).  A major complication was defined as Grade III, IV or V of the Clavien-
Dindo classification.  A wound infection was defined as per the United States Centre for Disease 
Control and Prevention (CDC) for surgical site infection (SSI)(13).  Anastomotic leak was 
defined as an intestinal wall defect at the site of the anastomosis with a direct communication 
between the intra- and extraluminal compartments(14).  Sepsis was defined as proof of 
bacteraemia or clinical suspicion of sepsis, as well as signs and symptoms of systemic 
inflammatory response syndrome(15).  An intra-abdominal collection was defined as an 
organised collection of fluid or pus diagnosed on imaging(16).  Inpatient mortality was defined 





The primary endpoints were the general major complications and predictive factors for major 
morbidity following pelvic exenterative surgery for locally advanced and recurrent pelvic 
malignancies. 
Statistical Analysis: 
Baseline characteristics were summarised using descriptive statistics.  All categorical data were 
analysed using either Fisher’s exact or Pearson-chi square test and continuous data using the 
student t-test.  The Kaplan-Meier method was used to estimate the 5-year overall survival, with a 
sub-analysis performed assessing patients’ survival by comparing pelvic exenteration for primary 
and recurrent pelvic tumours and major complications.  Logistic regression analysis was 
performed to identify independent risk factors for major morbidity.  All analysis was undertaken 
using IBM Corporation Released 2017, IBM SPSS Statistics for Windows, Version 25.0. 















A total of 646 consecutive patients requiring exenterative surgery for local advanced or recurrent 
pelvic malignancies between 1990 and 2015 were identified from the combined databases of two 
tertiary surgical institutions.  The median age for this cohort of patients was 63 years (range 19-
89 years), and the majority were female patients (371; 57.4%).    The baseline patient 
characteristics are outlined in Table 1.  The majority of exenterations were performed for 
primary disease (64.4%) and gastrointestinal adenocarcinoma histological subtype (70.0%). 
 
Patient Characteristic Total 
N = 646 (%) 
 
Sex  
Male 275 (42.6%) 
Female 371 (57.4%) 
 
Age  
<60 263 (40.7%) 
>60 383 (59.3%) 
 
ASA Score  
1 62 (9.6%) 
2 374 (57.9%) 
3 195 (30.2%) 
4 15 (2.3%) 
 
Prior Chemotherapy  
Yes 378 (58.5%) 
No 268 (41.5%) 
 
Prior Radiotherapy  
Yes 343 (53.1%) 
No 303 (46.1%) 
  
Disease Type  
Primary 416 (64.4%) 
Recurrent 230 (35.6%) 
 
Tumour Type  
GI Adenocarcinoma 452 (70.0%) 
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Anal SCC 42 (6.5%) 
Gynaecological 72 (11.1%) 
Other 80 (12.4%) 
Table 1: Baseline patient and tumour characteristics. 
 
Five hundred and forty patients did not suffer a major complication (83.6%) following pelvic 
exenterative surgery.  The major complications observed in the remaining 106 patients (16.4%) 
are outlined in Table 2.  Some patients experienced more than one major complication.  The 
most common major complications were intra-abdominal collection (43.7%; n=59/135) and 
wound infection (14.1%; n=19/135).  The frequency of anastomotic leak (1.5%; n=10/646) and 
post-operative bleeding (0.93%; n=6/646) requiring intervention were very low in this series.  
The overall inpatient mortality rate was 0.46%, occurring in 3 patients within this series.  One 
patient died from a pulmonary embolus and the other two patients died from septicaemia.  
 
Variables Total 
Major complications 106 patients 
(16.4%) 
Wound Infection 19 (14.1%) 
Pneumonia 4 (3.0%) 
UTI 3 (2.2%) 
Septicaemia 5 (3.7%) 
Myocardial infarction 3 (2.2%) 
Arrythmia 3 (2.2%) 
Pulmonary embolus 3 (2.2%) 
Stroke 1 (0.7%) 
Acute kidney injury 10 (7.4%) 
Acute respiratory distress syndrome 5 (3.7%) 
Intestinal anastomotic leak 10 (7.4%) 
Intra-abdominal collection 59 (43.7%) 
Post-operative bleeding 6 (4.4%) 
Small bowel obstruction 4 (3.0%) 
 
Table 2:  Major complications following pelvic exenterative surgery in 106 patients.  Some patients 
suffered more than one major complication.  Total number of major complications were 135 with wound 




There was no difference in major morbidity between age, ASA, primary or recurrent tumour, 
number of organs resected, radiotherapy and chemotherapy (Table 3).  Certain medical 
comorbidities, types of organs resected, formation of an ileal conduit and requirement for a blood 
transfusion were all associated with major morbidity on univariate analysis (Table 3).  
 






Sex    
Male 218 (40.4) 57 (53.8)  
Female 322 (59.6) 49 (46.2) 0.013 
    
Age    
<60 219 (40.6) 44 (41.5)  
≥60 321 (59.4) 62 (58.5) 0.829 
    
ASA score    
I 37 (8.5) 3 (3.3)  
II 250 (57.3) 54 (58.7)  
III 134 (30.7) 33 (35.9)  
IV 15 (3.4) 2 (2.2) 0.287 
    
Co-morbidities    
Myocardial Infarction 32 (5.9) 10 (9.4) 0.195 
Peripheral Vascular Disease 4 (0.7) 3 (2.8) 0.091 
Respiratory Disease 20 (3.7) 9 (8.5) 0.039 
Chronic Renal Failure 12 (2.2) 6 (5.7) 0.096 
Psychiatric history 24 (4.4) 10 (9.4) 0.053 
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Tumour    
Primary 351 (65) 65 (61.3)  
Recurrent 189 (35) 41 (38.7) 0.506 
    
Tumour type    
GI Adenocarcinoma 381 (70.6) 71 (67)  
Anal SCC 30 (5.6) 12 (11.3)  
Gynaecological 62 (11.4) 10 (9.4)  
Others 67 (12.4) 13 (12.3) 0.072 
    
Types of Organ Removed    
Colon 92 (17) 18 (17) NS 
Rectum 376 (70.9) 75 (70.8) NS 
Anus 98 (18.5) 27 (25.5) NS 
Small bowel 99 (18.3) 21 (19.8) NS 
Vagina 110 (20.4) 25 (23.6) NS 
Uterus 161 (29.8) 16 (15.1) 0.002 
Ovaries 188 (34.8) 21 (19.8) 0.002 
Prostate 93 (17.2) 32 (30.2) 0.003 
Bladder 141 (26.1) 41 (38.7) 0.013 
Sacrum 78 (14.4) 30 (28.3) 0.001 
    
Other Procedures    
Ileal conduit 109 (20.2) 40 (37.7) <0.001 
Rectus flap 110 (20.4) 31 (29.2) 0.053 
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Number of Organ Removed    
1 80 (14.8) 9 (8.5)  
2 147 (27.2) 29 (27.4)  
3 165 (30.6) 39 (36.8)  
4 104 (19.3) 15 (14.2)  
5 23 (4.3) 10 (9.4)  
6 6 (1.1) 2 (1.9)  
Missing 15 (2.8) 2 (1.9) 0.114 
    
Radiotherapy    
No 258 (47.8) 45 (42.5)  
Yes 282 (52.2) 61 (57.5) 0.339 
    
Chemotherapy    
No 222 (41.1) 46 (43.4)  
Yes 318 (58.9) 60 (56.6) 0.668 
    
Mean red blood cell packs (SD) 1.18 (3.2) 2.6 (7.3) <0.001 
 
Table 3: Patient, tumour, surgical and medical factors examined for an associated with major 
morbidity. 
 
Independent predictors for major morbidity following exenterative surgery for locally advanced 
or recurrent pelvic malignancies were squamous cell carcinoma of anus, sacrectomy, past history 











Squamous cell cancer 2.21 1.06 4.62 0.035 
Sacrectomy 1.81 1.08 3.05 0.026 
Peripheral vascular disease 5.19 1.04 25.82 0.044 
Hx of respiratory disease 2.34 0.99 5.48 0.051 
Blood transfusion 1.05 1.01 1.10 0.015 
 
Table 4: Logistic regression analysis – independent predictors for major morbidity highlighting that 























Complex major surgery is usually associated with significant complications(17) and this radical 
surgery is performed in the setting of advanced tumour growth and frequently irradiated tissue, 
thus exenterative surgery is commonly associated with major morbidity(18).  A systematic 
review of pelvic exenteration reported complication rates between 37% and 100%, whilst 
perioperative mortality rates ranged from 0% to 25%(19).  More recently, the PelvEx 
collaborative reported a 30-day major complication rate of 37.8% and 1.5% 30-day mortality rate 
following pelvic exenteration for locally advanced rectal cancer.  Furthermore, other high-
volume centres have reported improved serious complication rates (27%) following exenterative 
surgery for gynaecological malignancies(20).  This large study of exenterative surgery for locally 
advanced and recurrent pelvic malignancies has shown good short-term outcomes can be 
achieved in specialist centres with a coordinated approach.  The low 30-day major morbidity 
(16.4%) and inpatient mortality rates (0.46%) demonstrate this to be safe and feasible, supporting 
the argument that specialist centres with centralised care pathways are key to improving patient 
outcomes. Moreover, it is noted that appropriate patient selection is critical to improved 
outcomes which coincides with a thorough MDT process and stringent documentation of 
morbidity and morbidity.  
A common potential complication for the ever-expanding complex oncological surgery is the 
risk of massive intra-operative and postoperative haemorrhage and the subsequent blood 
transfusion requirement(21).  Several factors, including tumour characteristics, neoadjuvant 
chemoradiotherapy, anatomical features of the surgical area (eg. vascular proximity), complexity 
of surgery, explain the significant risk of bleeding and transfusion requirements in oncology 
patients(21).  The mean red blood pack cell transfusion requirement was 2.6 (SD+/- 7.3) in the 
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major morbidity group compared to 1.18 (SD+/- 3.2) in the non-major morbidity group 
(p<0.001).  Blood transfusion requirement was shown to be an independent predictor for major 
complication (OR 1.05; 95%CI 1.01-1.10; p=0.015) in this study.  This is supported by a study 
analysing 18,891 patients that underwent coronary artery bypass graft surgery, which showed 
that greater blood transfusion was independently associated with increased risk of mortality and 
major morbidity after adjusting for potential cofounders(22).  Moreover, a meta-analysis 
investigating the effects of blood transfusion on clinical outcomes in patients undergoing 
colorectal cancer surgery, demonstrated blood transfusions were associated with adverse clinical 
outcomes(23).  It is the effect of allogeneic transfusions inducing immune suppression, which 
explains the independent predictor of morbidity and mortality(24-26).    
Moreover, the definition of resectability has changed in the management of advanced pelvic 
malignancy(27), with more radical resections showing benefits in overall survival(5, 8).  This 
complexity of surgery includes en-bloc sacral excisions to ensure clear margins, which are now 
performed routinely in specialist centres(28).  However, the wider excision required to improve 
oncological outcomes comes at a cost, creating a larger defect and this increased complexity in 
surgery correlates with major postoperative morbidity(20).   Sacrectomy was shown to be an 
independent predictor for major complication (OR 1.81; 95% CI 1.08-3.05; p=0.026) in this 
study.   
Salvage surgery for residual or recurrent anal squamous cell carcinoma after primary treatment, 
although uncommon, when it is necessary, the residual/recurrent disease pattern requires a 
locally extensive operation to avoid positive margins(29).  The extensive surgery often required 
to achieve a clear margin is also likely reflected by the multifocality and more aggressive tumour 
biology of anal squamous cell carcinoma(30, 31).  These aspects likely explain the predictive 
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factor of anal squamous cell carcinoma for major morbidity after exenterative surgery (OR 2.21; 
95% CI 1.06-4.62; p=0.035), which is associated with high morbidity in other reported series(29, 
32, 33).  
There are several limitations to this study, which need to be considered.  Firstly, the study is 
retrospective, albeit based on data collected prospectively from two centres.  Interpretation of 
these results are limited somewhat by the degree of heterogeneity, both within each and between 
centres.  This includes, the degree of heterogeneity of the patient populations and variations in 
the treatment strategies and surgical technique.  It is also important to acknowledge that the data 
is collected over a long time period (1990-2015), which may also introduce a degree of inherent 
bias, given the evolving treatment strategies over time.  However, there is a previous 
collaborative history(2, 11, 28), with also a high degree of consistency of approach across the 
centres included in this study.  Therefore, in the absence of prospective studies, this report 
provides further data on the short-term complications and predictors following exenterative 
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Mini-Abstract: The aims were to analyse the major morbidity and factors predicting 
complications and long-term outcomes following a urological procedure within exenterative 
surgery.  Six hundred and forty-six patients from two specialist centres were evaluated.  The 
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major complication rate following a urological procedure was 28.3%.  Urological procedures 




BACKGROUND:  Extensive multi-visceral resection, including components of the urinary 
tract, is often required to achieve clear resection margins, which is now well established as a key 
predictor of long-term survival for locally advanced pelvic tumours.  The aims of this study were 
to analyse the major morbidity and factors predicting complications and long-term outcomes 
following a urological procedure within exenterative surgery. 
METHODS:  Data were collected from prospective databases at two high-volume institutions 
specialising in exenterative surgery for locally advanced and recurrent pelvic malignancies 
between 1990 and 2015.  The primary endpoints were general complications following 
urological and non-urological procedures in exenterative surgery and factors influencing 
complications and overall survival. 
RESULTS:  A total of 646 consecutive patients requiring exenterative surgery for local 
advanced or recurrent pelvic malignancies were identified.  The median age was 63 years (range 
19-89 years), the majority were female (371; 57.4%).   A urological intervention was performed 
in 226 patients (35.0%).  The overall 30-days major complication rate was significantly higher in 
the urological intervention group (28.3%; n=64) compared to the non-urological group (12.4%; 
n=52 patients; p=0.001).  Intestinal anastomotic leak (p=0.005) and intra-abdominal collections 
(p=0.001) were more common in the urological cohort.  Poor independent prognostic markers for 
5-year overall survival following a urological procedure were recurrent tumour, cardiovascular 
disease, previous thromboembolic event and post-operative PE.  A positive survival benefit was 
demonstrated in patients that received neo-adjuvant radiotherapy (HR 0.54; 95% CI 0.34-0.85; 
p=0.007). 
 
CONCLUSION:  Major complications, particularly intestinal anastomotic leak and intra-
abdominal collection, are more common in patients undergoing a urological procedure within 
pelvic exenterative surgery, impacting on 5-year overall survival.   





The oncological role of pelvic exenteration for locally advanced and recurrent pelvic 
malignancies arising from the anorectum, gynaecological or urological systems is now well 
established(1-3). 
The beyond TME collaborative provides consensus on the definitions and principles of 
management of these complex patients, advocating an extended surgical resection beyond the 
TME plane to achieve a pathological R0 resection(1).  Extensive multi-visceral resection is often 
required to achieve clear resection margins (R0), which is now well established as a key 
predictor of long-term survival for locally advanced pelvic tumours(4, 5).  To achieve an R0 
resection, an en-bloc multi-visceral resection with partial or complete cystectomy or resection of 
the ureter/s may be required in 20-53% of patients undergoing a pelvic exenteration(6-8).  
Urinary tract reconstruction after both cystectomy and partial ureter resection is associated with 
more specific complications in the context of locally advanced colorectal cancer surgery 
compared with primary urothelial cancer surgery(9, 10).  Prior pelvic radiotherapy and extent of 
surgical resection are two factors suggested for this increased urological morbidity(9, 11).   
However, there appears to be some disparity in reported specific morbidity outcomes following 
urological procedures in this context(12).  There is also a paucity of literature on general 
complications and outcomes following a urological procedure within exenterative surgery for 
locally advanced or recurrent pelvic malignancies. 
The aims of this study were to assess the general major morbidity related to urological 
procedures following exenterative surgery for locally advanced and recurrent pelvic 
malignancies.  Moreover, to evaluate the frequency of major complications in exenterative 
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surgery between urological and non-urological procedures.  Finally, to investigate potential 

























A retrospective review of prospectively maintained databases was undertaken to assess the 
outcome of patients who have undergone pelvic exenterative surgery for locally advanced pelvic 
malignancies.  The primary objectives were to identify the types of general complications 
following urological procedures compared with non-urological procedures, patient and surgical 
factors predicting complications and long-term outcomes following exenterative surgery for 
locally advanced pelvic tumours.  Two tertiary referral centres with specialist experience in the 
surgical management of advanced pelvic tumours, similar surgical approaches to beyond TME 
surgery and previous collaborative experience(2, 13) were included.  These institutions were 
Christchurch Hospital (Christchurch, New Zealand) and Peter MacCallum Cancer Centre 
(Melbourne, Australia).  All patients were routinely discussed at a dedicated pelvic exenterative 
surgery multidisciplinary meeting.  The diagnosis of locally advanced pelvic tumour was based 
on preoperative radiological imaging and clinical assessment.  Data were prospectively collected 
at individual institutions.  Patient demographics (age, sex, ASA), comorbidities, primary or 
recurrent tumour, tumour type, neoadjuvant & adjuvant regimen, organs resected and type of 
surgery including the need for urological or bony resection or flap reconstruction were recorded.  
Furthermore, the type of general complications (number of major complications: wound 
infection, pneumonia, urinary tract infection, sepsis, myocardial infarction, arrhythmias, 
pulmonary embolus, stroke, acute renal failure, acute respiratory distress syndrome, anastomotic 
leak, intra-abdominal collection, post-operative bleeding and small bowel obstruction) were 




Overall survival (OS) was defined as the time from the date of surgery to the date of death from 
any cause.   
Operations were considered exenterative when the primary organ and at least one of the 
surrounding organs was removed en-bloc (rectum, bladder, prostate, uterus, vagina, sacrum, 
small bowel, ureter, iliac vessels, ovary and fallopian tube removal)(13). 
Patients analysed included the following pathologies; gastrointestinal adenocarcinoma, anal 
squamous cell carcinoma (SCC), gynaecological (ovarian, cervical, uterine or vaginal) and other 
malignancy (melanoma, prostate, sarcoma, GIST and chordoma) and had surgically resected 
organs recorded prospectively. 
Resection of primary disease was defined as newly diagnosed malignant process requiring up 
front pelvic exenteration based on clinical and radiological assessment.  Recurrent disease was 
defined as newly diagnosed disease of similar histological characteristics as previously resected 
tumour with an R0 margin. 
A urological intervention was defined as a partial or complete excision of any genitourinary 
organ in men and any urinary tract organ in women, +/- urinary tract reconstruction (eg. ileal 
conduit).  Incontinent ileal conduits were constructed as per Bricker and the ureteroenteric 
anastomoses according to either the Bricker or Wallace techniques(14). 
Complications occurring within 30-days postoperatively or during the inpatient care for the index 
operation were graded according to the Clavien-Dindo classification system for surgical 
complications(15).  A major complication was defined as Grade III, IV or V of the Clavien-
Dindo classification.  A wound infection was defined as per the United States Centre for Disease 
Control and Prevention (CDC) for surgical site infection (SSI)(16).  Anastomotic leak was 
defined as an intestinal wall defect at the site of the anastomosis with a direct communication 
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between the intra- and extraluminal compartments(17).  Sepsis was defined as proof of 
bacteraemia or clinical suspicion of sepsis, as well as signs and symptoms of systemic 
inflammatory response syndrome(18).  An intra-abdominal collection was defined as an 
organised collection of fluid or pus diagnosed on imaging(19).  Inpatient mortality was defined 
as a death occurring within 30-days of the index procedure. 
Endpoints: 
The primary endpoints were the general complications following urological and non-urological 
procedures in pelvic exenterative surgery and factors influencing complications and overall 
survival for locally advanced and recurrent pelvic malignancies. 
Statistical Analysis: 
Baseline characteristics were summarised using descriptive statistics.  All categorical data were 
analysed using either Fisher’s exact or Pearson-chi square test and continuous data using the 
student t-test.  The Kaplan-Meier method was used to estimate the 5-year overall survival, with a 
sub-analysis performed assessing patients’ survival by comparing pelvic exenteration for primary 
and recurrent pelvic tumours and major complications.  Cox regression analysis was performed 
to identify independent risk factors for short- and long-term survival. This included entering 
post-operative complications as part of the analysis to assess its effect on survival after adjusting 
for patient, pathological and operative factors.  All analysis was undertaken using IBM 
Corporation Released 2017, IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: 







A total of 646 consecutive patients requiring exenterative surgery for local advanced or recurrent 
pelvic malignancies between 1990 and 2015 were identified from the combined databases of two 
tertiary surgical institutions.  The median age for this cohort of patients was 63 years (range 19-
89 years), and the majority were female patients (371; 57.4%).   A urological intervention was 
performed in 226 patients (35.0%).  The baseline characteristics of urological intervention and 
non-urological intervention are outlined in Table 1.  
Patient Characteristic Urological intervention 
N = 226 (%) 
 
Non-Urological intervention 
N = 420 (%) 
 
Total 
Sex    
Male 158 (69.9%) 117 (27.9%) 275 
Female 68 (30.1%) 303 (72.1%) 371 
 
Age    
<60 93 (41.2%) 170 (40.5%) 263 
>60 133 (58.8%) 250 (59.5%) 383 
 
ASA Score    
1 18 (8.0%) 44 (10.4%) 62 
2 130 (57.5%) 244 (58.1%) 374 
3 75 (33.2%) 120 (28.6%) 195 
4 3 (1.3%) 12 (2.9%) 15 
 
Prior Chemotherapy    
Yes 144 (63.7%) 234 (55.7%) 378 
No 82 (36.3%) 186 (44.3%) 268 
 
Prior Radiotherapy    
Yes 131 (58.0%) 212 (50.5%) 343 
No 95 (42.0%) 208 (49.5%) 303 
    
Disease Type    
Primary 167 (73.9%) 249 (59.3%) 416 
Recurrent 59 (26.1%) 171 (40.7%) 230 
 
Tumour Type    
GI Adenocarcinoma 161 (71.2%) 291 (69.3%) 452 
Anal SCC 13 (5.8%) 29 (6.9%) 42 
 
 72 
Gynaecological 22 (9.7%) 50 (11.9%) 72 
Other 30 (13.3%) 50 (11.9%) 80 
Table 1. Patient demographics of urological and non-urological interventions 
 
Operative details 
In the urological intervention group, a total cystectomy was performed in 149 patients (65.9%) 
and all had an incontinent ileal conduit formed.  Twenty-seven patients (11.9%) underwent a 
rectal resection and prostatectomy without cystectomy as part of the pelvic exenteration, a 
technique previously described(20).  The remaining urological procedures were a variety of 
ureteric resections and/or partial cystectomy (n=50; 22.1%). 
Overall complications 
The overall 30-day major complication rate for the urological intervention group was 28.3% 
(n=64 patients) and the type of major complications are outlined in Table 2.  The rate of overall 
30-days major complication rate was significantly higher in the urological intervention group 
compared to the non-urological group (12.4%; n=52 patients; p=0.001).  Acute renal failure 
(p=0.038), intestinal anastomotic leak (p=0.005) and intra-abdominal collections (p=0.001) were 
more common in the urological intervention cohort compared to the non-urological group (Table 
2).  There was no difference in the inpatient mortality rates between the two groups.  There was 
one death in the urological intervention group (0.4%) from a pulmonary embolus and two 
inpatient deaths in the non-urological cohort (0.5%) from septicaemia.  There was no association 
between major complications and requirement for a blood transfusion within the urological 












Major complications    
No 162 (71.7%) 368 (87.6%)  
Yes 64 (28.3%) 52 (12.4%) 0.001 
 
Wound Infection    
No 220 (97.3%) 407 (96.9%)  
Yes 6 (2.7%) 13 (3.1%) 0.813 
 
Pneumonia    
No 224 (99.1) 418 (99.5)  
Yes 2 (0.9) 2 (0.5) 0.615 
 
UTI    
No 224 (99.1) 419 (99.8)  
Yes 2 (0.9) 1 (0.2) 0.281 
 
Septicaemia    
No 224 (99.1) 417 (99.3)  
Yes 2 (0.9) 3 (0.7) 1 
 
Myocardial infarction    
No 224 (99.1) 419 (99.8)  
Yes 2 (0.9) 1 (0.2) 0.281 
 
Arrythmia    
No 225 (99.6) 418 (99.5)  
Yes 1 (0.4) 2 (0.5) 1 
 
Pulmonary embolus    
No 224 (99.1) 419 (99.8)  
Yes 2 (0.9) 1 (0.2) 0.281 
 
Stroke    
No 225 (99.6) 420 (100)  
Yes 1 (0.4) 0 0.35 
 
Acute renal failure    
No 219 (96.9) 417 (99.3)  
Yes 7 (3.1) 3 (0.7) 0.038 
 
Acute respiratory distress syndrome    
No 225 (99.6) 416 (99.0)  




Intestinal anastomotic leak    
No 218 (96.5) 418 (99.5)  
Yes 8 (3.5) 2 (0.5) 0.005 
 
Intra-abdominal collection    
No 193 (85.4) 394 (93.8)  
Yes 33 (14.6) 26 (6.2) 0.001 
 
Post-operative bleeding    
No 226 (100) 414 (98.6)  
Yes 0 6 (1.4) 0.096 
 
Small bowel obstruction    
No 223 (98.7) 419 (99.8)  
Yes 3 (1.3) 1 (0.2) 0.126 
Table 2: Major complications associated with urological and non-urological procedures.  A total of 64 
patients suffered one or more major complications in the urological procedure group, compared with 52 
patients with one or more major complications in the non-urological group. 
 
Outcomes analysis 
The overall 1-year mortality rate in the urological intervention cohort was 14.2% (n=32 patients).  
Table 3 outlines the patient, tumour and operative characteristics for this cohort of patients.  A 
past medical history of cardiovascular disease, previous malignant diagnosis or thromboembolic 
event were significant patient factors for 1-year mortality on univariate analysis (Table 3).  Anal 
squamous cell carcinoma pathology and the requirement of a small bowel resection were also 
significant factors (Table 3).  There was a tendency towards major morbidity in the group 
requiring an ileal conduit, but this was not statistically significant (p=0.067).  Independent 
predictors for 1-year mortality in the urological procedure group were anal squamous cell 














Sex       
Male 148 (76.3) 22 (68.8)  131 (75.3) 39 (75.0)  
Female 46 (23.7) 10 (31.3) 0.380 43 (24.7) 13 (25.0) NS 
       
Age       
<60 82 (42.5) 11 (34.4)  72 (41.6) 21 (40.4)  
≥60 111 (57.5) 21 (65.6) 0.442 101 (58.4) 31 (59.6) NS 
       
Past Medical History       
Myocardial infarction 18 (9.3) 2 (6.3) NS 13 (7.5) 7 (13.5) 0.263 
Stroke 8 (4.1) 2 (6.3) NS 8 (4.6) 2 (3.8) NS 
Peripheral vascular disease 1 (0.5) 0 NS 1 (0.6) 0 NS 
COPD 6 (3.1) 1 (3.1) NS 6 (3.4) 1 (1.9) NS 
Cardiovascular Disease 25 (12.9) 9 (28.1) 0.034 24 (13.8) 10 (19.2) 0.377 
Respiratory Disease 11 (5.7) 1 (3.1) NS 8 (4.6) 4 (7.7) NS 
Previous thromboembolic 
event 
6 (3.1) 4 (12.5) 0.038 6 (3.4) 4 (7.7) 0.244 
Chronic renal disease  8 (4.1) 3 (9.4) 0.192 7 (4.0) 4 (7.7) 0.282 
Diabetes 23 (11.9) 0 0.052 20 (11.5) 3 (5.8) 0.302 
Previous malignancy 
diagnosis 
22 (11.2) 8 (25.0) 0.047 22 (12.6) 8 (15.4) NS 
Smoker 29 (14.9) 2 (6.3) 0.269 23 (13.2) 8 (15.4) NS 
       
Tumour       
Primary 125 (64.4) 16 (50)  110 (63.2) 31 (59.6)  
Recurrent 69 (35.6) 16 (50) 0.167 64 (36.8) 21 (40.4) NS 
       
Tumour type       
GI Adenocarcinoma 151 (77.8) 24 (75.0)  134 (77.0) 41 (78.8)  
Anal SCC 10 (5.2) 6 (18.8)  11 (6.3) 5 (9.6)  
Gynaecological 10 (5.2%) 0  7 (4.0) 3 (5.8)  
Other 23 (11.9) 2 (6.2) NS 22 (12.7) 3 (5.8) NS 
       
Types of Organ Removed       
Colon 28 (14.4) 5 (15.6) NS 22 (12.6) 11 (21.2) 0.177 
Rectum 139 (71.6) 21 (65.6) NS 128 (73.6) 32 (61.5) 0.117 
Anus 32 (16.6) 5 (15.6) NS 28 (16.2) 9 (17.3) NS 
Small bowel 46 (23.7) 15 (46.9) 0.009 47 (27.0) 14 (26.9) NS 
Vagina 21 (10.9) 7 (21.9) 0.089 18 (10.4) 10 (19.2) 0.098 
Uterus 15 (7.7) 5 (15.6) 0.173 17 (9.8) 3 (5.8) NS 
Ovaries 21 (10.8) 5 (15.6) 0.384 22 (12.6) 4 (7.7) NS 
Prostate 108 (55.7) 17 (53.1) NS 93 (53.4) 32 (61.5) NS 
Bladder 153 (78.9) 29 (90.6) 0.151 141 (81.0) 41 (78.8) NS 
Sacrum 38 (19.6) 4 (12.5) NS 32 (18.4) 10 (19.2) NS 
       
No of Organs Removed       
1 6 (3.1) 1 (3.1)  6 (3.4) 1 (1.9)  
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2 42 (21.6) 6 (18.8)  37 (21.3) 11 (21.2)  
3 83 (42.8) 8 (25.0)  69 (39.7) 22 (42.3)  
4 45 (23.2) 11 (34.4)  47 (27.0) 9 (17.3)  
5 14 (17.2) 4 (12.5)  11 (6.3) 7 (13.5)  
6 2 (1.0) 2 (6.3)  3 (1.7) 1 (1.9)  
Missing 2 (1.0) 0 0.164 1 (0.6) 1 (1.9) NS 
       
Other Procedures       
Stoma 153 (78.9)  29 (90.6) 0.151 136 (78.2) 46 (88.5) 0.113 
Ileal conduit 124 (63.9) 25 (78.1) 0.158 109 (62.6) 40 (76.9) 0.067 
Rectus flap 42 (21.6) 10 (31.3) 0.258 41 (23.6) 11 (21.2) NS 
       
Radiotherapy       
No 70 (36.1) 17 (53.1)  69 (39.7) 18 (34.6)  
Yes 124 (63.9) 15 (46.9) 0.079 105 (60.3) 34 (65.4) 0.626 
       
Chemotherapy       
No 69 (35.6) 14 (43.8)  66 (37.9) 17 (32.7)  
Yes 125 (64.6) 18 (56.3) 0.430 108 (62.1) 35 (67.3) NS 
 






95%CI for OR 
p-value 
Lower Upper 
Squamous cell cancer 4.54 1.43 14.35 0.010 
Small bowel resection 2.90 1.29 6.50 0.010 
Acute kidney injury 8.04 1.60 40.44 0.011 
Table 4: Independent predictors for 1-year mortality 
 
There was no difference in the 5-year overall survival between the urological and non-urological 
intervention group (Figure 1).  However, analysis of 5-year overall survival in the urological 
group showed a difference between patients that suffered a major complication and those that did 
not (Figure 2).  Poor independent prognostic markers following proportional hazards regression 
analysis for 5-year overall survival in the urological procedure group were recurrent tumour 
(Figure 3), joint anal surgery, previous malignant diagnosis, cardiovascular disease, previous 
thromboembolic event and post-operative PE (Table 5).  A positive survival benefit was 









Recurrent tumour resection 2.56 1.59 4.14 <0.001 
Radiation therapy 0.54 0.34 0.85 0.007 
Joint anal surgery 2.01 1.19 3.37 0.009 
Hx of cardiovascular disease 1.91 1.10 3.34 0.022 
Previous thromboembolic event 6.17 2.70 14.1 <0.001 
Previous malignant diagnosis 1.83 1.03 3.24 0.039 
Post-operative PE 7.83 1.02 60.16 0.048 
Table 5: Cox Regression Analysis on 5-year overall survival in the urological procedures group. 
 
 




Figure 2: Five-year overall survival between major complications and no major complications within 



















This large international combined series from established centres, specialising in pelvic 
exenterative surgery, describes the patterns of general complications and presents good overall 
outcomes for urological procedures performed as part of the management of locally advanced 
and recurrent pelvic malignancies.  Overall, 35.0% (n=226 patients) of all patients required a 
urological procedure as part of the pelvic exenteration, which is a similar frequency to other 
large series(6, 8, 12).    
Pelvic exenteration has previously been associated with a high incidence of perioperative 
complications with rates ranging from 32% to 84%(3).  However, evolution in the surgical 
techniques has steadily been gaining momentum, with improved outcomes(21, 22), therefore it is 
no longer deemed a palliative procedure(23).  Recently, the PelvEx Collaborative reported a 30-
day major complication rate of 37.8% among all patients undergoing exenteration for locally 
advanced rectal cancer(5).  Moreover, a study investigating the patterns of complications 
following urological intervention in pelvic exenterative surgery demonstrated a major 
complication rate of 35% (67/189 patients)(24).  This study presents favourable 30-day major 
general morbidity rates of 28.3% for the urological intervention group and 12.4% for the non-
urological intervention group.  The inpatient mortality rate was also lower in this study compared 
with rates ranging from 1.5% to 15.6%(5, 7, 24). 
The major general complication rate was significantly higher in the urological intervention group 
compared with the non-urological group (p=0.001), which was reflected predominantly by the 
increased frequency of intestinal anastomotic leak and intra-abdominal collections (Table 2).  A 
recent study evaluating short-term outcomes following pelvic exenteration for gynaecological 
malignancy demonstrated a similar serious morbidity rate (27%)(25).  Surgical complexity is a 
 
 81 
main driver of complications, with urological procedures being associated with significantly 
more complications(25).  The increase in intra-abdominal collections within the urological 
intervention group might reflect the nature of the surgery performed, particularly ileal conduit 
formation or reconstruction following ureteric resection, representing urine leaks.  However, this 
can only be postulated as the database did not capture this specific information on urine leaks.  
The increased dead space within the pelvic inlet following a total pelvic exenteration may also 
further explain this observed outcome(26).   The frequency of major intra-abdominal collections 
were similar to other reported series of 13.7%(27).   
The increased number of intestinal anastomotic leaks in the urological intervention group (3.5% 
n=8) likely reflects the increased frequency of anastomoses performed in relation to ileal 
conduits formation.  An ileal conduit was the method of choice for reconstruction of the urinary 
tract following total cystectomy because the majority of patients receive neoadjuvant 
radiotherapy, limiting the option of orthotopic bladder substitutes(28).  Also, continent urinary 
reconstruction options do not consistently provide improved quality of life(29).  The intestinal 
anastomotic leak rate has been reported as high as 9% following a urological procedure(24).  
Possible risk factors for increased morbidity in pelvic exenterative surgery include prior pelvic 
irradiation, however, this remains uncertain(6, 9, 11, 30).  In this study, neoadjuvant radiotherapy 
did not impact on major general complications in the urological intervention group (p=0.626).  
An association between poorer overall survival and post-surgical complications has been 
observed in colorectal cancer patients(31).  This study also showed that development of a major 
complication impacted 5-year overall survival (Figure 2) in the urological intervention group.  
This effect might be explained by the systemic consequence of the complication on the patient 
and/or causing delay or rendering the patient unsuitable for further adjuvant therapies(28). 
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Two independent poor prognostic markers for 5-year overall survival were pulmonary embolus 
and previous thromboembolic events. The long-term consequence of pulmonary embolus is well 
known, due to nearly 50% of the patients are likely to continue suffering from serious adverse 
events, such as recurrent venous thromboembolism, cardiovascular events, chronic pulmonary 
hypertension and death(32).  Assessment of patient comorbidities prior to surgical intervention is 
an integral part of risk-stratification because of the direct correlation between the increasing 
mean age of cancer patients and the presence of one or more comorbidities(33).  In cancer 
patients above the age of 65, approximately 60% will have one or more comorbidity; in which 
23% were associated with cardiovascular disease(34).  Cardiovascular disease was also an 
independent poor prognostic predictor for 5-year overall survival in this study, consistent with 
other studies showing it to be a significant predictor of in-patient mortality(35) and poorer 5-year 
overall survival(36).  
This highlights that patient comorbidities and specific complications can influence long-term 
survival, emphasising the importance of an individualised discussion and treatment plan for 
patients requiring pelvic exenterative surgery.  Patients must be counselled accordingly when 
considering surgical intervention and this study further aids in the process of informed consent 
for patients, explaining the pathological, technical complexities and patient factors leading to 
poorer outcomes and affecting survival. 
There are several limitations to this study, which need to be considered.  Firstly, the study is 
retrospective, albeit based on data collected prospectively from two centres.  Interpretation of 
these results are limited somewhat by the degree of heterogeneity, both within each and between 
centres.  This includes, the degree of heterogeneity of the patient populations and variations in 
the treatment strategies and surgical technique.  It is also important to acknowledge that the data 
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is collected over a long-time period (1990-2015), which may also introduce a degree of inherent 
bias, given the evolving treatment strategies over time.  However, there is a previous 
collaborative history(2, 13, 37), with also a high degree of consistency of approach across the 
centres included in this study.  Therefore, in the absence of prospective studies, this report 
provides further data to the paucity of literature on general complications and prognostic 
outcomes following urological procedures as part of pelvic exenterative surgery for locally 
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In an era of personalised medicine, there is an overwhelming effort for predicting patients that 
will benefit from extended radical resections for locally advanced pelvic malignancy.  However, 
there is paucity of data on the effect of comorbidities and post-operative complications on long-
term overall survival (OS).  The aim of this study was to define predictors of one-year and five-
year OS. 
Methods: 
Data were collected from prospective databases at two high-volume institutions specialising in 
beyond TME surgery for locally advanced and recurrent pelvic malignancies between 1990 and 
2015.  The primary outcome measures were 1-year and 5-year OS. 
Results: 
A total of 646 consecutive extended radical resections were performed between 1990 and 2015.  
The majority were female patients (371, 57.4%) and the median age was 63 years (range 19-89 
years).  One-year OS, primary rectal adenocarcinoma had the best survival whilst recurrent colon 
cancer had the worse survival (p=0.047).  The 5-year OS between primary and recurrent cancers 
were 64.7% and 53% respectively (p=0.004).  Poor independent prognostic markers for 5-year 
OS were; increasing ASA score, cardiovascular disease, recurrent cancers, ovarian cancers, 
pulmonary embolus and acute respiratory distress syndrome. A positive survival benefit was 
demonstrated with pre-operative radiotherapy (HR 0.55; 95%CI 0.4-0.75, p<0.001). 
Conclusion: 
Patient comorbidities and specific complications can influence long-term survival following 
extended radical resections.  This study highlights important predictors, enabling clinicians to 
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better inform patients of the potential short and long-term outcomes in the management of 




Pelvic exenteration was first described as an en-bloc removal of the pelvic organs for advanced 
or recurrent cancers(1). Previously, such a radical approach have significant post-operative 
consequence, with reported 30-day mortality rate of 17.2%, 2-year overall survival (OS) of 27% 
and 5-year OS of 17%.(2) Subsequently, through improvements in perioperative care and 
surgical technique, current accepted mortality rates are 1.1-2% and 5-year OS of 40-48.6%.(3-6) 
Therefore, pelvic exenteration has shifted from a palliative surgical approach to providing 
appropriately selected patients with a chance for cure. 
In an era of personalised medicine, there is an overwhelming effort for predicting those that will 
benefit most from extended radical resections(4, 6, 7). This will not only aid in patient selection 
for such a morbid procedure, but informed consent. However, most studies have only assessed 
surgical and pathological variables as significant influence on long-term outcomes. There is 
paucity of data on the effect of comorbidities and post-operative complications on long-term OS.  
The aim of this study was to define predictors of one-year and five-year OS based on patient 







This was a retrospective observational study of a prospectively maintained database from two 
tertiary teaching hospitals, Peter MacCallum Cancer Centre, Australia and Christchurch 
Hospital, Canterbury District Health Board, New Zealand.  All patients were routinely discussed 
at a dedicated pelvic exenterative surgery multidisciplinary meeting.  The diagnosis of locally 
advanced or recurrent pelvic tumour was based on preoperative radiological imaging and clinical 
assessment.  
Clinical data was entered into an electronic database; which includes patient comorbidities (age, 
American Society of Anaesthesiologist (ASA) score, myocardial infarction, stroke, peripheral 
vascular disease, asthma, chronic obstructive pulmonary disease, cardiovascular disease, 
respiratory disease, thromboembolic events, chronic renal failure, diabetes, previous malignancy, 
smoker), surgical procedure (number of organs removed and reconstructive method), type of 
treatment (blood transfusion, pre-operative chemotherapy and radiotherapy), pathology and 
complications (number of major complications, pneumonia, urinary tract infection, sepsis, 
myocardial infarction, arrhythmias, pulmonary embolus, stroke, acute renal failure, acute 
respiratory distress syndrome, anastomotic leak, intra-abdominal collection, post-operative 
bleeding, ileus and small bowel obstruction). 
Definitions: 
Operations were considered extended radical resections when the primary organ and at least one 
of the surrounding organs was removed en-bloc(8). 
Patients analysed included the following pathologies: rectal adenocarcinoma, colonic 
adenocarcinoma, anal squamous cell carcinoma (SCC), ovarian cancer, other gynaecological 
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(cervical, uterine or vaginal) malignancy and other malignancy (melanoma, prostate, sarcoma, 
GIST and chordoma). 
Complications occurring within 30-days postoperatively or during the inpatient care for the index 
operation were graded according to the Clavien-Dindo classification system for surgical 
complications(9).  A major complication was defined as Grade III, IV or V of the Clavien-Dindo 
classification.  A wound infection was defined as per the United States Centre for Disease 
Control and Prevention (CDC) for surgical site infection (SSI)(10).  Anastomotic leak was 
defined as an intestinal wall defect at the site of the anastomosis with a direct communication 
between the intra- and extraluminal compartments(11).  Sepsis was defined as proof of 
bacteraemia or clinical suspicion of sepsis, as well as signs and symptoms of systemic 
inflammatory response syndrome(12).  An intra-abdominal collection was defined as an 
organised collection of fluid or pus diagnosed on imaging(13).   
Statistical analysis: 
The primary outcome measures were 1-year and 5-year OS. Descriptive analysis was performed 
accordingly; all categorical data were analysed using either Fisher’s exact or Pearson-chi square 
test and continuous data using the student t-test. A Kaplan-Meir survival curve was performed to 
ascertain 1-year and 5-year OS, with a sub-analysis performed assessing patients’ survival by 
comparing extended radical resection for primary and recurrent colorectal cancers. Cox 
regression analysis was performed to identify independent risk factors for short- and long-term 
survival. This includes entering post-operative complications as part of the analysis to assess its 
effect on survival after adjusting for patient, pathological and operative factors.  
All analysis was undertaken using IBM Corporation Released 2017, IBM SPSS Statistics for 
Windows, Version 25.0. Armonk, NY: IBM Corporation. A p<0.05 was considered significant.  
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The protocol and methods of this study were reviewed and approved by the institutional ethics 
committee of the Peter MacCallum Cancer Centre.      
Results 
There was a total of 646 consecutive extended radical resections between 1990 and 2015.  The 
majority were female patients (371, 57.4%) and the median age was 63 years (range 19-89 
years). The pathological characteristics were 416 (64.4%) primary cancers and 230 (35.6%) 
recurrent cancers, with the majority confirmed to be adenocarcinoma 452 (70%). The median 
follow-up was 4 years (range 0.2-29.1 years). There was only one death within 30-days and the 
one-year mortality rate was 12.2% (79 patients). 
Univariate analysis for one-year mortality is shown in Tables 1 and 2. Older patients (more than 
70 years old; p=0.039), higher ASA score (III and IV; p=0.006), histology confirmation of SCC 
or ovarian cancer (p=0.015) and known history of cardiovascular disease (p<0.001) were shown 
to be significant predictors of poorer one-year overall survival.  
Variables Alive (%) One-year 
mortality (%) 
p-value 
Sex    
Male 246 (43.4) 29 (36.7)  
Female 321 (56.6) 50 (63.3) 0.277 
    
Age    
18-29 11 (1.9) 2 (2.5)  
30-49 100 (17.6) 5 (6.3)  
50-69 297 (52.4) 40 (50.6)  
70-79 130 (22.9) 28 (35.4)  
≥80 29 (5.1) 4 (5.1) 0.039 
    
ASA score    
I 37 (7.9) 3 (4.8)  
II 279 (59.9) 25 (40.3)  
III 136 (29.2) 31 (50)  
IV 14 (3.0) 3 (4.8)  
V 0 0 0.006 
Missing 101 17  
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Tumour    
Primary 363 (64) 53 (67.1)  
Recurrent 204 (36) 26 (32.9) 0.619 
    
Tumour type    
Adenocarcinoma 402 (70.9) 50 (63.3)  
SCC 33 (5.8) 9 (11.4)  
Gynaecological malignancy 15 (2.6) 2 (2.5)  
Ovarian cancer 44 (7.8) 13 (16.5)  
Others 73 (12.9) 5 (6.3) 0.015 
    
Types of Organ Removed    
Colon 90 (15.9) 20 (25.3) 0.054 
Rectum 403 (71.1) 48 (60.8) 0.068 
Anus 111 (19.9) 14 (17.7) NS 
Small bowel 93 (16.4) 27 (34.2) <0.001 
Vagina 117 (20.7) 18 (22.8) NS 
Uterus 154 (27.2) 23 (29.1) NS 
Ovaries 183 (32.3) 26 (32.9) NS 
Prostate 108 (19.0) 17 (21.5) NS 
Bladder 153 (27.0) 29 (36.7) 0.083 
Sacrum 99 (17.5) 9 (11.4) NS 
    
Other Procedures    
Stoma 391 (69.0) 61 (77.2) NS 
Ileal conduit 124 (21.9) 25 (31.6) 0.063 
Rectus flap 125 (22.0) 16 (20.3) NS 
 
Table 1: Patient, tumour and operative characteristics of all pelvic exenteration patients  
 
The influence of post-operative complications on short-term survival was also assessed, showing 
a statistically significant negative impact on survival as shown in Table 2. However, blood 
transfusion did not show any difference between those that had survived compared to those that 








Variables Alive (%) One-year 
mortality (%) 
p-value 
Co-morbidities    
History of cardiovascular disease 76 (13.4) 24 (30.4) <0.001 
Previous thromboembolic disease 25 (4.4) 8 (10.1) 0.050 
Previous myocardial infarction 34 (6.0) 8 (10.1) 0.218 
Previous stroke 18 (3.2) 3 (3.8) 0.734 
Peripheral vascular disease 5 (0.9) 2 (2.5) 0.207 
Chronic obstructive pulmonary disease 20 (3.5) 5 (6.3) 0.215 
Chronic renal failure 15 (2.6) 3 (3.8) 0.474 
Diabetes mellitus 58 (10.2) 7 (8.9) 0.843 
Previous malignancy 66 (11.6) 14 (17.7) 0.143 
Smoker 71 (12.5) 7 (8.9) 0.461 
    
Major Complications    
No 485 (85.5) 55 (69.6)  
Yes 82 (14.5) 24 (30.4) 0.001 
    
Septicaemia    
No 565 (99.6) 76 (96.2)  
Yes 2 (0.4) 3 (3.8) 0.015 
    
Pulmonary embolus    
No 566 (99.8) 77 (97.5)  
Yes 1 (0.2) 2 (2.5) 0.041 
    
Acute Renal Failure    
No 561 (98.9) 75 (94.9)  
Yes 6 (1.1) 4 (5.1) 0.024 
    
Acute Respiratory Distress Syndrome    
No 565 (99.6) 76 (96.2)  
Yes 2 (0.4) 3 (3.8) 0.015 
    
Intra-abdominal Collection    
No 520 (91.7) 67 (84.8)  
Yes 47 (8.3) 12 (15.2) 0.059 
    
Mean red blood cell packs (SD) 1.33 (4.1) 2.00 (5.0) 0.185 
    
Radiotherapy    
No 256 (45.1) 47 (59.5)  
Yes 311 (54.9) 32 (40.5) 0.022 
    
Chemotherapy    
No 226 (39.9) 42 (53.2)  
Yes 341 (60.1) 37 (46.8) 0.028 




In a sub-analysis of recurrent cancers, the majority were adenocarcinoma (173 patients - 75.2%) 
followed by SCC (24 patients - 10.4%) and gynaecological malignancy (10 patients - 4.3%). 
Preoperative radiotherapy or chemotherapy were commonly given to recurrent compared to 
primary cancers as shown in Table 3. There was no difference in major complications; however, 






Sex    
Male 163 (39.2) 112 (48.7)  
Female 253 (60.8) 118 (51.3) 0.020 
    
Age    
18-29 10 (2.4) 3 (1.3)  
30-49 72 (17.3) 33 (14.3)  
50-69 207 (49.8) 130 (56.5)  
70-79 103 (24.8) 55 (23.9)  
≥80 24 (5.8) 9 (3.9) 0.402 
    
Tumour type    
Adenocarcinoma 279 (67.1) 173 (75.2)  
SCC 18 (4.3) 24 (10.4)  
Gynaecological malignancy 7 (1.7) 10 (4.3)  
Ovarian cancer 53 (12.7) 4 (1.7)  
Others 59 (14.2) 19 (8.3) <0.001 
    
Organ resection    
Colon 85 (20.4) 25 (10.9) 0.002 
Rectum 291 (70.0) 160 (69.6) 0.929 
Anus 78 (18.9) 47 (21.0) 0.533 
Small bowel  62 (14.9) 58 (25.3) 0.001 
Vagina 70 (16.9) 65 (28.3) 0.001 
Uterus 125 (30.0) 52 (22.6) 0.043 
Ovaries 160 (38.5) 49 (21.3) <0.001 
Prostate 82 (19.7) 43 (18.7) 0.754 
Bladder 126 (30.3) 56 (24.3) 0.121 
Sacrum 37 (8.9) 71 (30.9) <0.001 
    
Clinical T stage    
T3    
Rectal adenocarcinoma 30 (66.7) 11 (52.4)  
Colon carcinoma 10 (22.2) 2 (9.5)  
Others 5 (11.1) 8 (38.1) 0.030 
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T4    
Rectal adenocarcinoma 117 (65.0) 29 (54.7)  
Colon carcinoma 50 (27.8) 7 (13.2)  
Others 13 (7.2) 17 (32.1) <0.001 
    
T stage not mentioned  191 156  
    
Clinical N stage    
N0    
Rectal adenocarcinoma 61 (24.5) 60 (54.5)  
Colon carcinoma 66 (26.5) 11 (10.0)  
Others 122 (49.0) 39 (35.5) <0.001 
    
N1    
Rectal adenocarcinoma 54 (75.0) 11 (57.9)  
Colon carcinoma 13 (18.1) 2 (10.5)  
Others 5 (6.9) 6 (31.6) 0.013 
    
N2    
Rectal adenocarcinoma 45 (77.6) 3 (100)  
Colon carcinoma 10 (17.2) 0  
Others 3 (5.2) 0 0.652 
    
N stage not mentioned 37 98  
    
Pre-operative radiation therapy    
No 224 (53.8) 79 (34.3)  
Yes 192 (46.2) 151 (65.7) <0.001 
    
Rectal cancer pre-operative radiation    
No 45 (24.9) 31 (22.0)  
Yes 136 (75.1) 110 (78.0) 0.598 
    
Colon cancer pre-operative radiation    
No 69 (71.1) 10 (38.5)  
Yes 28 (28.9) 16 (61.5) 0.003 
    
Others    
No 110 (79.7) 38 (60.3)  
Yes 28 (20.3) 25 (39.7) 0.006 
    
Pre-operative chemotherapy    
No 187 (45.0) 81 (35.2)  
Yes 229 (55.0) 149 (64.8) 0.019 
    
Major complications    
No 351 (84.4) 189 (82.2)  
Yes 65 (15.6) 41 (17.8) 0.506 
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Blood transfusion    
<2 units 347 (83.4) 155 (67.4)  
≥2 units 69 (16.6) 75 (32.6) <0.001 
    
1-year OS 87.3% 88.7% 0.619 
Rectal adenocarcinoma 91.2% 90.8%  
Colon carcinoma 85.6% 76.9%  
Others 83.3% 88.9%  
    
5-year OS 64.7% 53.0% 0.004 
Rectal adenocarcinoma 74.6% 52.5%  
Colon carcinoma 60.8% 50.0%  
Others 54.3% 55.6%  
 
Table 3: Patient, tumour and operative characteristics between primary and recurrent cancers 
 
One-year OS, primary rectal adenocarcinoma had the best survival whilst recurrent colon cancer 







 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 6.076 2 .048 
Breslow (Generalized 
Wilcoxon) 
6.111 2 .047 
Tarone-Ware 6.105 2 .047 
Test of equality of survival distributions for the different levels of 
AdenoCaSite. 
a. Adjusted for Tumour (Primary vs Recurrent). 
 
Figure 1: One-year survival for primary and recurrent cancers  
 
The 5-year OS between primary and recurrent cancers were statistically significant, with an 










 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 8.405 2 .015 
Breslow (Generalized 
Wilcoxon) 
12.704 2 .002 
Tarone-Ware 10.798 2 .005 
Test of equality of survival distributions for the different levels of 
AdenoCaSite. 






Figure 2: 5-year overall survival for primary and recurrent cancers 
Poor independent prognostic markers for 5-year OS were; increasing ASA score, history of 
cardiovascular disease, recurrent cancers, ovarian cancers, pulmonary embolus and acute 
respiratory distress syndrome (see Table 4). A positive survival benefit was demonstrated if 




95%CI for OR  
Lower Upper p-value 
One-year Overall Survival 
Patient comorbidities     
ASA score     
1 1.00    
2 1.18 0.34 4.07  
3 3.35 0.99 11.37  
4 2.95 0.57 15.12 <0.001 
     
Peripheral vascular disease 5.24 1.21 22.7 0.027 
Previous malignancy 2.04 1.06 3.89 0.032 
     
Treatment     
Rectal resection 0.48 0.27 0.82 0.008 
Small bowel resection 2.12 1.21 3.71 0.008 
Radiation therapy 0.44 0.25 0.78 0.005 
     
Complications     
Septicemia 7.07 1.23 40.7 0.029 
Pulmonary embolus 70.59 15.2 327.1 <0.001 
ARDS 11.11 3.34 36.95 <0.001 
Anastomotic leak 5.00 1.43 17.51 0.012 
Post-operative bleeding 6.14 1.40 26.89 0.016 
     
5-year Overall Survival 
Patient comorbidities     
ASA score     
1 1.00    
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2 0.79 0.47 1.34  
3 1.43 0.84 2.44  
4 1.22 0.52 2.87 0.004 
     
Cardiovascular disease 1.57 1.11 2.22 0.011 
     
Pathology     
Recurrent cancers 1.84 1.35 2.52 <0.001 
Ovarian cancers 2.57 1.73 3.81 <0.001 
     
Treatment     
Pre-operative radiotherapy 0.55 0.40 0.75 <0.001 
Complications     
Pulmonary embolus 15.32 3.68 63.7 <0.001 
ARDS 3.82 1.38 10.6 0.010 
     
5-year Overall Survival without complications 
Patient comorbidities     
ASA score     
1 1.00    
2 0.76 0.45 1.28  
3 1.31 0.77 2.23  
4 1.29 0.55 3.03 0.007 
     
Cardiovascular disease 1.67 1.19 2.35 0.003 
     
Pathology     
Recurrent cancers 1.76 1.29 2.41 <0.001 
Ovarian cancers 3.03 2.01 4.57 <0.001 
     
Treatment     
Pre-operative radiotherapy 0.57 0.42 0.78 <0.001 
Anal resection 1.85 1.31 2.60 <0.001 
 Blood transfusion 1.03 1.01 1.06 0.013 
Table 4: Cox regression analysis.  





In this retrospective analysis of a large dual tertiary hospital database, the risk of 30-day 
mortality is low, with an overall major complication rate of 16.4% and favourable 5-year OS for 
primary cancers compared to recurrent cancers. Patient comorbidities and specific complications 
can influence long-term survival and this study can further aid in patient informed consent, 
explaining not only the pathological and technical complexities affecting survival but also their 
comorbidities and potential complications leading to poorer outcomes. 
Nonetheless, it was noted for 5-year OS, primary colon cancers had a worse prognosis compared 
to the rectal cancer cohort. This was despite having more advanced clinical T and N stage, hence 
the judicious use of pre-operative radiotherapy. This can explain the better long-term outcome, 
with 75.1% of rectal cancer patients receiving radiotherapy before surgery compared to only 
28.9% for patients with advanced colonic cancers. Furthermore, major complications were 
equivalent between primary and recurrent cancers although blood transfusion requirement was 
significantly higher in the recurrent cancer cohort.  
Although the overall morbidity after surgery was lower than expected compared to the current 
reported literature,(14-16) it did identify two independent poor prognostic markers for 5-year 
OS; pulmonary embolus and acute respiratory distress syndrome. The long-term consequence of 
pulmonary embolus has been clearly defined, in which nearly 50% of the patients will continue 
to suffer from serious adverse events (within four years) such as recurrent venous 
thromboembolism, cardiovascular events, chronic pulmonary hypertension and death.(17) 
Knowing their increased risk of further adverse events, these patients may benefit from close 
monitoring not only to identify oncological recurrence but subsequent adverse events as a result 
of pulmonary embolus. This includes individualised assessment of the risk for recurrent venous 
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thromboembolism for prolonged anticoagulation consideration and effective cardiovascular risk-
factor evaluation and preventive treatment measures.(17) 
Patient comorbidities should be an integral part of risk stratification for any surgical procedure. 
As the population ages, so does the mean age of cancer patients and presence of one or more 
comorbidities.(18) It has been estimated that cancer patients above the age of 65 or older, 
approximately 60% will have one or more comorbidity; in which 23% were associated with 
cardiovascular disease.(19) Cardiovascular disease, notably heart failure has been shown to be a 
significant predictor of in-patient mortality(20) and have poorer 5-year OS.(21)  
Therefore, using a comprehensive prospectively collected database, specific patient 
comorbidities was examined. From our analysis, increasing ASA score and cardiovascular 
disease were significant predictors for 5-year OS, after adjusting for pathological, treatment and 
post-operative factors. Several reasons can contribute to poorer survival outcome for patients 
with known cardiovascular disease; the cardiotoxic and antiangiogenic effects commonly used 
during systemic and radiation therapies can exacerbate cardiac symptoms, lack of awareness and 
knowledge about cardiac health and suboptimal access to preventive care maybe the cause for 
these patients.(22) 
Our study is subject to both strengths and limitations. This study represents one of the largest 
cohorts, with extensive prospectively collected database and durable predictors of short- and 
long-term outcomes. However, it is based on a well selected group of patients of which surgery 
was performed in a highly specialised centre, hence the lower morbidity rate. Moreover, we were 
unable to extrapolate post-operative treatment (adjuvant chemotherapy or radiotherapy) that may 
be confounders to our current survival analysis. Finally, without knowing the cause of death, it is 
not possible to associate cause and effect of post-operative complications to long-term survival.  
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There are several limitations to this study, which need to be considered.  Firstly, the study is 
retrospective, albeit based on data collected prospectively from two centres.  Interpretation of 
these results are limited somewhat by the degree of heterogeneity, both within each and between 
centres.  This includes, the degree of heterogeneity of the patient populations and variations in 
the treatment strategies and surgical technique.  It is also important to acknowledge that the data 
is collected over a long-time period (1990-2015), which may also introduce a degree of inherent 
bias, given the evolving treatment strategies over time.  However, there is a previous 
collaborative history(8, 23, 24), with also a high degree of consistency of approach across the 
centres included in this study.  Therefore, in the absence of prospective studies, this report 
provides further data on the short-term complications and predictors following exenterative 
surgery for locally advanced and recurrent pelvic malignancies. 
There has only been one study examining this clinical research question. Huang et al. showed a 
none association was identified between patient’s comorbidities (for hypertension, pulmonary 
disease, cardiac disease, diabetes mellitus) with long-term oncological outcomes after pelvic 
exenteration for gynaecological malignancies.(25) Others have used chronological age or 
number of comorbidities to better select patients for pelvic exenteration and inconsistent 
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In chapter one this large international combined series from established centres specialising in 
pelvic exenterative surgery, presents good outcomes and describes the evolution of this 
technique for locally advanced pelvic tumours over thirty years. Surgical innovations over this 
time have led to multivisceral surgical intervention to treat locally advanced pelvic tumours and 
this data supports that these approaches have been steadily gaining momentum (1, 2).  During the 
course of the last three decades, this study demonstrates advances in the operative strategies 
implemented to improve both the potential of gaining an R0 resection margin thus improving 
oncological and patient outcomes. Moreover, the findings presented within, outline patient 
survival dependant on the types of pathology encountered. These findings are reported to educate 
both patients and the surgical community on the potential survival outcomes post-surgical 
intervention for each pathological subtype. The use of this data is imperative in guiding patient, 
family and surgical anticipated expectations and outcomes and to aid the pre-operative consent 
process.  
  This work documented that there was an increased incidence of patients undergoing 
exenterative surgery for recurrent disease during the latter years of this study (2011 to 2018) 
compared with the preceding time points. Furthermore, there was increasing complexity of 
surgical resections and the pathology encountered which was reflected by the expanding number 
of surgical compartments resected and operative components performed.  This correlation was 
further demonstrated by the increasing number of sacrectomy, ileal conduits and lateral pelvic 
sidewall dissections performed during the study period. With regards to survival, patients 
undergoing exenterative surgery in the most recent time period had significantly improved 
survival. The data also reported improved survival for primary over recurrent disease at each 
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specific time point except for 2005 – 2010. However, when examined in the total cohort primary 
disease undergoing exenteration had superior survival when compared to recurrent disease. 
These finding were borne out in smaller studies. A study examining outcomes of 40 consecutive 
exenterations over a nine year period for locally advanced versus locally recurrent colorectal 
malignancy reported that 5-year overall survival was significantly inferior in recurrent disease as 
opposed to upfront advanced disease (58.7% vs. 11.8%, P = 0.022) (3). When examining five-
year survival data, the latest cohort (2011 – 2018) had greatest survival benefit undergoing 
surgery for GI and gynaecological related malignancy. There was not a similar survival benefit 
observed in patents with squamous cell carcinoma and other malignancy (Melanoma, Prostate, 
Sarcoma, GIST and Chordoma). This current work supports smaller studies which have 
highlighted that non-modifiable factors associated with gynaecological malignancy at the time of 
exenteration are associated with poor survival (4). These outcomes have been mirrored in other 
studies (5, 6) A recent study reported an overall survival of 40.7% and cumulative 5-year overall 
survival of 38% in patients under exenterative surgery for primary and recurrent cervical 
carcinoma.  This combined data together with other smaller studies in the literature provides 
valuable data which aids in the already complex decision making of patients undergoing 
exenterative surgery.  
In chapter two it is reported through this retrospective analysis the risk of 30-day 
mortality is low, with an overall major complication rate of 16.4% and favourable 5-year OS for 
primary cancers compared to recurrent cancers. Complex major surgery has been shown to be 
associated with significant complications and this radical surgery is performed in the setting of 
advanced tumour growth and frequently irradiated tissue, thus exenterative surgery is commonly 
associated with major morbidity (7, 8). Moreover, a systematic review of pelvic exenteration 
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reported complication rates between 37% and 100%, whilst perioperative mortality rates ranged 
from 0% to 25% (9). This documents that patient comorbidities and specific complications can 
influence long-term survival and this study can further aid in patient informed consent, 
explaining not only the pathological and technical complexities affecting survival but also their 
comorbidities and potential complications leading to poorer outcomes. Nonetheless, it was noted 
for 5-year OS, primary colon cancers had a worse prognosis compared to the rectal cancer 
cohort. This was despite having more advanced clinical T and N stage, hence the judicious use of 
pre-operative radiotherapy. This can explain the better long-term outcome, with 75.1% of rectal 
cancer patients receiving radiotherapy before surgery compared to only 28.9% for patients with 
advanced colonic cancers. Furthermore, major complications were equivalent between primary 
and recurrent cancers although blood transfusion requirement was significantly higher in the 
recurrent cancer cohort. This low 30-day major morbidity (16.4%) and inpatient mortality rates 
(0.46%) demonstrate this to be safe and feasible, supporting the argument that specialist centres 
with centralised care pathways are key to improving patient outcomes. The series in this chapter 
adds to the increasing evidence that good outcomes can be achieved for pelvic exenterative 
surgery in locally advanced and recurrent pelvic malignancies.  A coordinated approach in 
specialist centres for beyond TME surgery demonstrates this is a safe and feasible procedure, 
offering low major complication rates. 
In the chapter three, the patterns of general complications are describe and it documents 
good overall outcomes for urological procedures performed as part of the management of locally 
advanced and recurrent pelvic malignancies. Urinary tract reconstruction after both cystectomy 
and partial ureter resection is associated with more specific complications in the context of 
locally advanced colorectal cancer surgery compared with primary urothelial cancer surgery(10, 
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11).  Prior pelvic radiotherapy and extent of surgical resection are two factors suggested for this 
increased urological morbidity. It is highlighted in this chapter that major complications, 
particularly intestinal anastomotic leak and intra-abdominal collection, are more common in 
patients undergoing a urological procedure within pelvic exenterative surgery which also impacts 
on 5-year overall survival.  Overall, 35.0% (n=226 patients) of all patients required a urological 
procedure as part of the pelvic exenteration, which is a similar frequency to other large series(12-
14). The overall 30-days major complication rate was significantly higher in the urological 
intervention group (28.3%; n=64) compared to the non-urological group (12.4%; n=52 patients; 
p=0.001).  Surgical complexity is a main driver of complications, with urological procedures 
being associated with significantly more complications(15).  The increase in intra-abdominal 
collections within the urological intervention group might reflect the nature of the surgery 
performed, particularly ileal conduit formation or reconstruction following ureteric resection, 
representing urine leaks. The increased dead space within the pelvic inlet following a total pelvic 
exenteration may also further explain this observed outcome (16).   The frequency of major intra-
abdominal collections were similar to other reported series of 13.7% (17). The data recognises an 
increased number of intestinal anastomotic leaks in the urological intervention group (3.5% n=8), 
this likely reflects the increased frequency of anastomoses performed in relation to ileal conduits 
formation.  An association between poorer overall survival and post-surgical complications has 
been observed in colorectal cancer patients (18).  This study also showed that development of a 
major complication impacted 5-year overall survival in the urological intervention group.  This 
effect might be explained by the systemic consequence of the complication on the patient and/or 
causing delay or rendering the patient unsuitable for further adjuvant therapies (19).  
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This chapter continues to reflect the cornerstone of this thesis in which advocates that 
clinical assessment of patient comorbidities prior to surgical intervention is an integral part of 
risk-stratification because of the direct correlation between the increasing mean age of cancer 
patients and the presence of one or more comorbidities. Furthermore, it aids in the individualised 
consenting process by highlighting that patient comorbidities and specific complications can 
influence long-term survival, emphasising the importance of an individualised discussion and 
treatment plan for patients requiring pelvic exenterative surgery.  Patients must be counselled 
accordingly when considering surgical intervention and this study documents the necessity in 
explaining the pathological, technical complexities and patient factors leading to poorer 
outcomes and affecting survival to both patient and family members. 
 Chapter four delved deeper into investigating the impact of co-morbidities and post-
operative complications on long term overall survival in patients undergoing pelvic exenteration. 
It is reported in this chapter that when analysing one-year overall survival, primary rectal 
adenocarcinoma had the best survival whilst recurrent colon cancer had the worse survival 
(p=0.047).  The 5-year OS between primary and recurrent cancers were 64.7% and 53% 
respectively (p=0.004).  Patient comorbidities should be an integral part of risk stratification for 
any surgical procedure. As the population ages, so does the mean age of cancer patients and 
presence of one or more comorbidities.(20) It has been estimated that cancer patients above the 
age of 65 or older, approximately 60% will have one or more comorbidity; in which 23% were 
associated with cardiovascular disease.(21) Cardiovascular disease, notably heart failure has 
been shown to be a significant predictor of in-patient mortality and have poorer 5-year OS (22, 
23). Poor independent prognostic markers for 5-year OS were; increasing ASA score, 
cardiovascular disease, recurrent cancers, ovarian cancers, pulmonary embolus and acute 
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respiratory distress syndrome. A positive survival benefit was demonstrated with pre-operative 
radiotherapy. Several reasons can contribute to poorer survival outcome for patients with known 
cardiovascular disease; the cardiotoxic and antiangiogenic effects commonly used during 
systemic and radiation therapies can exacerbate cardiac symptoms, lack of awareness and 
knowledge about cardiac health and suboptimal access to preventive care maybe the cause for 
these patients. 
Patient comorbidities and specific complications can influence long-term survival following 
extended radical resections.  This study highlights important predictors, enabling clinicians to 
better inform patients of the potential short and long-term outcomes in the management of 
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